Approach To Psychotic Symptoms
A systematic clinical evaluation of hallucinations, delusions, and disorganized thinking to differentiate primary psychotic disorders from secondary causes such as medical conditions, substance use, and mood disorders.
Psychosis (思覺失調) is a syndrome broadly defined as a "loss of contact with reality" [1]. Let's unpack that word: "psychosis" comes from Greek psyche (mind) + -osis (abnormal condition) — literally, an abnormal condition of the mind.
It is characterised by four cardinal features [1][2]:
- Delusions — an abnormal belief that is (1) firmly held on inadequate grounds, (2) unshakeable by counter-argument, and (3) out of keeping with the person's social and cultural background
- Hallucinations — perceptions in the absence of external stimuli (distinguish from illusions, which are misperceptions of real stimuli)
- Disorganization — of both thinking (formal thought disorder) and behaviour (bizarre, purposeless conduct)
- Lack of insight — the patient does not recognise that their experiences are pathological
The critical conceptual point: psychosis is a syndrome, not a diagnosis [1][2]. Just as "fever" can be caused by infection, malignancy, or autoimmune disease, psychosis can result from schizophrenia, mood disorders, organic brain disease, or substance use. Your job is to identify the underlying cause.
Psychosis vs Neurosis
Psychosis vs. neurosis is a classical psychiatric distinction [1]. In psychosis, reality testing is impaired — the patient believes their delusions and hallucinations are real. In neurosis (e.g., anxiety, OCD), reality testing is preserved — the patient recognises their symptoms as excessive or irrational, even if they cannot control them. This distinction, while somewhat dated, remains clinically useful as a first-pass categorisation.
Psychotic disorder is a disease of the brain [1]. Although the precise aetiological basis remains incompletely understood, it is currently defined clinically (i.e., by symptom pattern and course rather than by biomarkers). The Chinese term in Hong Kong, adopted since 2001, is 思覺失調 [1] — literally "disorder of thought and perception," which beautifully captures the two core domains (delusions = thought; hallucinations = perception).
2. Epidemiology
| Parameter | Value | Source |
|---|---|---|
| Prevalence of all psychotic disorders | ~2–3% | [1] |
| Lifetime prevalence of psychotic disorders in Hong Kong | 2.5% (Chang et al. 2017) | [1] |
| Lifetime risk of schizophrenia | ~1% | [1][2] |
| Median incidence of schizophrenia | 15.2 per 100,000 per year | [1] |
| Incidence range across regions | 7.7–43 per 100,000 per year | [1] |
Why does the incidence vary so widely across regions? Because psychosis is not purely genetic — socio-environmental factors strongly modulate risk. Specifically [1]:
- Migrants of ethnic minority (especially from developing countries to Western developed countries, e.g., UK, Netherlands) have elevated rates compared to locally-born Caucasians — this is the "migration effect," thought to relate to social defeat, discrimination, and marginalisation
- Urban upbringing (urbanicity) confers higher risk vs rural areas — possibly via chronic social stress, pollution, or reduced social cohesion
- Onset usually in late adolescence and early adulthood [1][2]
- Male to female risk ratio for schizophrenia = 1.4:1 [1][2]
- Men have an earlier age at onset than women [1][2]:
- Males: typically 18–25 years
- Females: bimodal — first peak at 25–35 years, second peak at perimenopause (oestrogen is thought to be partially protective → loss at menopause unmasks vulnerability)
- Schizophrenia is traditionally described as a high-prevalence, low-incidence disease (i.e., it is chronic in nature — people accumulate in the prevalent pool because they don't recover fully) [2]
- No. 12 leading disability worldwide with substantial direct and indirect costs [2]
- Suicide is the single largest cause of premature death in schizophrenia [2]:
- Lifetime suicide risk: 5.6% (highest in the first year of illness — because depressed mood, a strong predictor of suicide, is frequently observed early)
- 12× general population suicide risk
- Lifespan reduced by 10–15 years on average [2]
- 2.6× all-cause mortality, with the majority being non-suicidal causes [2]:
- Lifestyle factors (sedentary, poor nutrition)
- Smoking, substance/alcohol abuse
- Metabolic syndrome secondary to 2nd-generation antipsychotics
- Possibly inherent disease process → accelerated ageing and medical morbidity
High Yield: Schizophrenia Mortality
A common exam mistake is to assume most excess deaths in schizophrenia are from suicide. While suicide risk is markedly elevated, the majority of excess mortality is from non-suicidal causes — particularly cardiovascular disease, metabolic syndrome, and respiratory disease. Always consider metabolic monitoring for patients on antipsychotics.
| Condition | Lifetime Risk | Key Demographics |
|---|---|---|
| All psychotic disorders | 2–3% | — |
| Schizophrenia | ~1% | M > F, young adults |
| Schizoaffective disorder | 0.3% (~1/3 of schizophrenia) | Early adulthood |
| Delusional disorder | 0.05–0.1% | Median onset 46 years, over-represented by women |
| Schizotypal PD | 0.6–4.6% | Familially aggregates with schizophrenia |
| Bipolar disorder (spectrum) | 0.3–1.6% (BD-I), 3.7% (spectrum) | M:F ≈ 1:1, mean onset ~18y |
3. Risk Factors
Understanding risk factors for psychosis requires a stress-vulnerability model [1]: genetic liability creates a "vulnerable brain," and environmental stressors (at various developmental stages) push the individual over a threshold into clinical psychosis.
- High degree of heritability: estimated ~80% [1][2]
- Polygenic architecture: multiple genes, each with small individual effects [1]
- Many identified candidate genes relate to dopamine, glutamate, synaptic functions, and immune mechanisms [1]
- Rare copy number variants (CNVs) with larger effect [1]:
- Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome / Velo-cardio-facial syndrome, VCFS) — associated with 20–30 fold increase in risk of schizophrenia [1]
- This is the single strongest known genetic risk factor for schizophrenia
- Family risk data [1]:
- First-degree relatives: 10–15% risk
- Monozygotic twin: ~50% concordance (note: not 100%, so environment clearly matters)
- Shared genetic risk between schizophrenia, bipolar disorder, MDD, schizoaffective disorder, and autism [3]
These are subdivided into distal (prenatal/perinatal) and proximal (later life) factors [1]:
Distal (prenatal & perinatal) risk factors:
- Obstetric complications (hypoxia, preeclampsia, emergency Caesarean section) — disrupt normal neurodevelopment
- Winter birth / maternal infections (e.g., influenza, toxoplasmosis) — maternal immune activation during critical periods of fetal brain development may disrupt neuronal migration and synaptic formation
- Advanced paternal age at conception — mechanism: accumulation of de novo mutations and/or epigenetic changes in sperm
Proximal social risk factors:
- Substance abuse, especially cannabis — cannabis (particularly high-potency THC) increases dopamine release in the mesolimbic pathway; adolescent use during the critical neurodevelopmental window is especially harmful
- Migration (ethnic minority status) — the "social defeat" hypothesis: chronic exposure to social exclusion/discrimination sensitises the dopamine system
- Urbanicity (urban upbringing) — mechanisms overlap with social defeat; may also include environmental toxins, population density stress
These are unified under the social defeat hypothesis / stress-dopamine sensitisation model [1]: chronic social adversity → sustained stress response → sensitisation of mesolimbic dopaminergic transmission → ↑vulnerability to psychosis.
- Gene × environment interactions are emphasised [1] — genetic vulnerability determines how much environmental stress is needed to cross the psychosis threshold.
- Low IQ / intellectual disability — associated with higher risk of schizophrenia [1]
- Poor premorbid adjustment — social and academic difficulties in childhood/adolescence
- Family history (as above)
- Expressed emotions (EE): critical, hostile, or emotionally over-involved attitudes from relatives [2]
- ↑risk of relapse if exposed to environment of high EE > 35 hours/week
- Association seen in schizophrenia, bipolar disorder, alcoholism, learning disabilities
4. Anatomy and Function: Key Neural Circuits in Psychosis
To understand psychotic symptoms from first principles, you need to know the four major dopamine pathways [1][2]. These are central to both symptom generation and treatment side effects:
| Pathway | Origin → Target | Normal Function | Relevance to Psychosis |
|---|---|---|---|
| Mesolimbic | Ventral tegmental area (VTA) → nucleus accumbens, amygdala, hippocampus (limbic system) | Reward, motivation, emotional salience | Hyperdopaminergic transmission → positive symptoms (delusions, hallucinations) [1] |
| Mesocortical | VTA → prefrontal cortex (dorsolateral and ventromedial) | Executive function, working memory, social cognition, motivation | Hypodopaminergic transmission → negative symptoms and cognitive deficits [1] |
| Nigrostriatal | Substantia nigra → dorsal striatum (caudate and putamen) | Voluntary motor control | Antipsychotics block D2 here → extrapyramidal side effects (EPS) [1] |
| Tuberoinfundibular | Hypothalamus → pituitary gland | Tonically inhibits prolactin release via D2 | Antipsychotics block D2 here → hyperprolactinaemia [1] |
Why Antipsychotics Cause Side Effects
All typical (first-generation) antipsychotics and some atypicals work by blocking D2 receptors. This is therapeutic in the mesolimbic pathway (reduces positive symptoms) but causes collateral damage:
- Block D2 in nigrostriatal → Parkinsonism, dystonia, akathisia, tardive dyskinesia
- Block D2 in tuberoinfundibular → ↑prolactin → galactorrhoea, amenorrhoea, sexual dysfunction, osteoporosis
- Block D2 in mesocortical → may worsen negative symptoms and cognitive deficits (the pathway is already hypodopaminergic!)
This is why atypical (second-generation) antipsychotics, which also antagonise 5-HT2A receptors, preferentially increase dopamine release in the mesocortical pathway while maintaining mesolimbic blockade — potentially improving negative/cognitive symptoms with fewer EPS.
- Glutamate (NMDA receptor hypofunction) [1][2]:
- NMDA receptor antagonists (phencyclidine, ketamine) can induce a schizophrenia-like psychosis — this was a key piece of evidence
- NMDA hypofunction may be developmental in origin
- Downstream effects: excessive dopamine release in mesolimbic system and neurotoxicity
- Excess glutamate neurotransmission → neurotoxicity / may lead to hyperdopaminergia [1]
- GABA [2]:
- Glutamic acid decarboxylase (GAD), the synthetic enzyme of GABA, is reduced in schizophrenic brain
- Reduced GABA levels seen on spectroscopy
- GABA interneurons normally regulate cortical excitatory-inhibitory balance — their dysfunction may contribute to cortical disorganisation
- Serotonin (5-HT) [2]:
- ↓5-HT2A and 5-HT1A receptor densities in frontal cortex
- Atypical antipsychotics often act as 5-HT2 antagonists — this is part of what makes them "atypical"
- LSD, a hallucinogen, is an agonist at 5-HT2 receptors — further evidence for serotonin's role in psychosis
- Volume reduction of entire brain and grey matter, especially in temporal lobe, prefrontal cortex, thalamus, and anterior cingulate
- ↑Ventricular volume (lateral and third ventricles) — one of the most replicated findings in schizophrenia
- ↓Cortical thickness and surface area
- Present to some extent at illness onset but continue to progress after illness
Functional changes [1]:
- Altered white matter connectivity (on diffusion tensor imaging, DTI)
- Altered resting-state functional integrity (on functional MRI)
Neuropathological findings [1][2]:
- Mainly ↓synapse-rich neuropil but without gliosis and without evidence of neuronal loss
- This is critically important: absence of gliosis + lack of neuronal loss speaks against neurodegeneration and supports a neurodevelopmental origin [1]
- Why? Because gliosis (astrocyte scarring) is the hallmark of acquired neuronal injury/death. Its absence implies the brain was never normal to begin with — the abnormality arose during development, not from later destruction.
Since psychosis can also arise from mood disorders, it's worth noting [4][5]:
- Depression: volume reduction and decreased glial cells in subgenual cortex, reduced hippocampal size [4]
- Dysregulation of HPA axis (hypothalamic-pituitary-adrenal) — cortisol hypersecretion in both depression and bipolar disorder [4][5]
- Abnormalities in ventromedial and dorsolateral prefrontal cortex function and amygdala-anterior cingulate connectivity [2]
5. Aetiology and Pathophysiology
This is the major hypothesis based on current evidence [1][2]. Rather than being acquired (degenerative), schizophrenia is primarily a neurodevelopmental disorder.
The Conceptual Model (see Fig. 1 in lecture slides [1]):
Evidence for the neurodevelopmental hypothesis [1]:
- Motor function deficits occur before onset of illness [1]
- Neurological soft signs (subtle motor and sensory abnormalities) are present premorbidly [1]
- Poor premorbid adjustment (academic and social) [1]
- Low IQ / intellectual disability associated with higher risk [1]
- Cognitive deficits emerge in the prodromal period [1]
- Neurobiology: no gliosis/neuronal loss suggests prenatal insult; structural brain changes present at or before illness onset with limited progression after onset [2]
- Most environmental risk factors are prenatal/perinatal in origin [2]
The trajectory: Genetic liability → prenatal insults → vulnerable brain → abnormal adolescent pruning → disconnectivity → prodromal cognitive/social decline → environmental triggers (stress, cannabis) → psychosis
Stress-vulnerability model for psychosis development [1]: the most practical clinical framework.
- Everyone has a certain threshold for developing psychosis, determined by their genetic/neurodevelopmental vulnerability
- Environmental stressors push individuals toward that threshold
- Individuals with high genetic vulnerability need relatively little stress to become psychotic
- Individuals with low genetic vulnerability may only develop psychosis under extreme stress (e.g., ICU delirium, heavy cannabis use)
This explains why:
- Not all identical twins are concordant (50%, not 100%)
- Cannabis is a risk factor in some people but not others (gene × environment)
- Social adversity (migration, urbanicity) increases risk population-wide
Increased pre-synaptic dopamine synthesis in the striatum is the core biochemical finding [1]. This is not simply "too much dopamine everywhere" — it is pathway-specific:
| Pathway | State in Schizophrenia | Consequence |
|---|---|---|
| Mesolimbic | Hyperdopaminergic | Positive symptoms (salience misattribution → delusions; aberrant sensory processing → hallucinations) |
| Mesocortical | Hypodopaminergic | Negative symptoms + cognitive deficits (reduced executive function, working memory, motivation) |
Why does the mesolimbic pathway become hyperdopaminergic? The current understanding is that it's a downstream consequence of upstream abnormalities — including NMDA receptor hypofunction on cortical glutamatergic neurons → loss of inhibitory regulation → disinhibition of subcortical dopamine release [1][2].
The "aberrant salience" model (Kapur, 2003): mesolimbic dopamine normally assigns "salience" (importance) to stimuli. In psychosis, dopamine is released in an unregulated fashion, attaching importance to irrelevant stimuli → the patient begins to find meaning in things that are meaningless → ideas of reference → delusions. Similarly, internal neural noise, normally suppressed, becomes salient → hallucinations.
Since psychosis can arise from mood disorders, understanding the pathophysiology of depression and bipolar disorder is relevant:
- Classical "serotonin hypothesis": diminished activity of serotonin pathways [4]
- But: the cause of depression is far more complicated than reduced serotonin [5]
- Monoamines including serotonin, norepinephrine, and dopamine are all relevant [5]:
- Serotonin: regulates body temperature, sleep-wakefulness, mood, and impulse control. Low serotonin metabolites in brains of suicide decedents and spinal fluids of depressed patients [5]
- Norepinephrine: regulates mood and anxiety levels. Mood symptoms emerged among patients taking propranolol [5]
- Dopamine: regulates motor and mental activity, attention and motivation. Dopaminergic neurons in mesolimbic reward pathway play important role in motivation, reinforcement, and pleasure response — diminished in brains of suicidal decedents with depression [5]
- Abnormalities in glutamate, GABA, and substance P also detected [5]
- Structural brain changes: volume reduction and decreased glial cells in subgenual cortex, reduced hippocampal size [4]
- Hormonal changes: HPA axis dysregulation, lower estradiol (women) and testosterone (men), decreased T3 and TSH, diminished BDNF [4]
- 79% heritability [3]
- Shared genetic risk between bipolar, schizophrenia, and autism [3]
- Some overlap with genes involving circadian rhythm regulation [3]
- Biochemical pathways: especially dopaminergic, second messengers, mitochondrial, HPA axis, and thyroid [3]
- Neuroimaging findings: structural and functional abnormalities [3]
- Infective causes, e.g., Toxoplasma gondii (the associated immune response) [3]
- Environmental factors: life events, social support, low care and overprotective parents, poor attachment relationship, childhood abuse, sleep deprivation, circadian and social rhythm disruption [3]
6. Classification of Psychotic Disorders
6.1 Primary (Psychiatric) Psychotic Disorders
The classification follows a hierarchical approach — essentially, you're asking: How long has the psychosis lasted? Are mood symptoms prominent? How bizarre are the features?
The prototypical psychotic disorder. Detailed separately but key distinguishing features [1][2]:
- Prominent psychotic symptoms lasting at least 1 month affecting functioning
- DSM-5 requires ≥6 months of disturbance including at least 1 month of active psychosis
- Content of delusions/hallucinations often bizarre in theme
- Schneider's first-rank symptoms (FRS), when present, are highly suggestive
- Mood disturbance, if any, is not concurrent with psychosis or is relatively minor
Symptom dimensions [2]:
- Positive symptoms: reality distortions (delusions, hallucinations)
- Negative symptoms: loss of normal functioning (5 A's)
- Disorganization: disorganized thoughts and behaviour/speech
- Affective symptoms: depression, anxiety, mania/hypomania
- Motor symptoms: catatonia, neurological soft signs
- Cognitive impairment
- Concurrent schizophrenic and mood symptoms are equally prominent [1]
- Psychotic features must be present before and after mood episodes
- Psychosis must exist for ≥2 weeks in the absence of a major mood episode (DSM-5) [2]
- Functional impact often less marked than schizophrenia [2]
- Prognosis better than schizophrenia (negative symptoms rarely develop) but worse than mood disorders [2]
- Whether this entity truly exists as distinct from schizophrenia or mood disorders is questionable — it is neither genetically nor neurobiologically separated [2]
Acute onset, complete remission, brief period [1]:
- ATPD: onset ≤2 weeks
- Brief psychotic disorder (DSM-5): duration < 1 month
- Schizophreniform disorder: duration 1–6 months (doesn't yet meet the 6-month schizophrenia threshold)
- May be precipitated by acute stress
- Polymorphic features (~cycloid psychosis): rapidly changing clinical pictures, prominent fluctuating mood state, perplexity [1]
Previously known as paranoid psychoses / paranoia [2]:
- Systematized, likely single-theme delusion, non-bizarre in nature [1]
- No or non-prominent hallucinations (if any, fleeting and related to delusions) [2]
- Minimal negative symptoms, better functioning reported [1]
- Over-represented by women and adult-onset [1]
- Relatively rare (0.05–0.1% lifetime risk, median age of onset 46 years) [2]
- Themes: persecutory (commonest), erotomania, jealous, somatic, grandiose [2]
- Encapsulated: behaviour unrelated to the delusion is often normal [2]
- A proportion may go on to develop full-blown schizophrenia [2]
- A pervasive pattern (stable course) of social/interpersonal deficits with [2]:
- Cognitive distortions (attenuated delusions): odd beliefs, ideas of reference, magical thinking, paranoid ideation
- Perceptual distortions (attenuated hallucinations): illusions, "sixth sense"
- Odd behaviour (attenuated disorganization): vague/circumstantial speech, eccentric appearance
- Social isolation (attenuated negative symptoms): few close friends, social anxiety
- Patient has never met criteria for schizophrenia throughout life [2]
- Considered personality disorder in DSM-5, but schizophrenia-like disorder in ICD-10 [2]
- Part of the schizophrenia-spectrum [1]
- Distinguish from schizoid personality disorder which has similar social isolation but no cognitive/perceptual distortions [2]
- Mood disturbances dominate the clinical picture [2]
- Content of psychosis is often mood-congruent [2]:
- Depression → nihilistic delusions ("my organs are rotting"), auditory hallucinations criticising them, delusions of guilt/poverty
- Mania → grandiose delusions ("I am God"), hallucinations affirming their special status
Will be discussed in the differential diagnosis section, but includes:
- Delirium (any cause)
- Substance use (intoxication or withdrawal)
- Neurological conditions (epilepsy, dementia, encephalitis, brain tumours)
- Metabolic/endocrine disorders (thyroid, Cushing's, porphyria)
- Autoimmune encephalitis (anti-NMDA receptor encephalitis — particularly important in young women)
7. Clinical Features of Psychotic Symptoms
7.1 Symptoms (Subjective Experiences)
A. Hallucinations — perception in the absence of external stimulus [2]
| Type | Frequency | Details | Pathophysiological Basis |
|---|---|---|---|
| Auditory hallucinations (AH) | Most common (40–80%) | Typically voices; can be sounds. Most responsive to antipsychotics | Aberrant activation of auditory cortex (superior temporal gyrus) due to hyperdopaminergia in mesolimbic pathway; internal speech misattributed to external source due to self-monitoring deficits (efference copy failure) |
| Visual hallucinations | Uncommon in primary psychosis | Usually unformed (glowing orbs, colours); typically with other hallucination types | If prominent: think organic cause (delirium, substance intoxication, Lewy body dementia) — because visual processing relies on widespread cortical networks more easily disrupted by metabolic/toxic insults |
| Other (somatic, olfactory, gustatory) | Rare | — | Olfactory: think temporal lobe epilepsy |
Forms of auditory hallucinations that are Schneider's First-Rank Symptoms (FRS): [2]
- Thought echo — voice repeating one's own thoughts aloud (the patient hears their thought spoken back)
- 3rd person AH — voices conversing with each other about the patient ("He is lazy"; "No, he is stupid")
- Running commentary — voices narrating the patient's actions in real-time ("He is sitting down now")
Schneider's First-Rank Symptoms (SPECTRA mnemonic) [2]:
- Somatic passivity (bodily sensations imposed by external force)
- Passivity experiences / delusions of control (thoughts, feelings, actions imposed)
- Echo of thought (auditory)
- Commentary, running (auditory)
- Thought insertion, withdrawal, broadcasting
- Reference, delusional perception (two-stage: normal perception → delusional meaning)
- Auditory 3rd person hallucinations
B. Delusions (80% of schizophrenia patients) [2]
A delusion is a fixed, false belief not in keeping with circumstances. Key dimensions:
-
Primary vs secondary [2]:
- Primary: arises spontaneously, de novo (e.g., suddenly "just knows" they are being followed)
- Secondary: derived as an explanation for other psychopathology (e.g., "a device has been implanted in my brain" to explain auditory hallucinations)
-
Bizarre vs non-bizarre [2]:
- Bizarre: completely impossible (e.g., "aliens replaced my brain with a computer") — more characteristic of schizophrenia
- Non-bizarre: somewhat understandable but false (e.g., "my neighbours are spying on me") — more characteristic of delusional disorder
-
Themes [2]:
- Referential (ideas of reference): TV, radio, or strangers are referring specifically to the patient
- Grandiose: inflated self-importance, special powers or identity
- Paranoid/persecutory: being followed, poisoned, plotted against — clinically important → violence risk
- Nihilistic: belief that self, others, or the world do not exist or are doomed (more common in psychotic depression; extreme form = Cotard's syndrome)
- Erotomanic: someone (usually of higher status) is in love with the patient
- Somatic: false belief about body function/sensation
- Passivity phenomena (FRS): belief that external forces control thoughts, feelings, or actions
Why do delusions form? (Pathophysiological basis) The aberrant salience hypothesis: mesolimbic hyperdopaminergia causes the brain to assign excessive significance to irrelevant stimuli → the patient seeks meaning in coincidences → crystallises into a fixed belief system (delusion). Cognitive biases (jumping to conclusions, attributional biases) then maintain the delusion.
Usually independent of severity of positive symptoms [2]. Grouped into the 5 A's under two clusters:
Diminished Expression (DE):
- Affect flattening — reduced facial expression, gesture, spontaneous movement, vocal intonation, eye contact
- Why? Hypodopaminergic mesocortical pathway → reduced frontal lobe activation → impoverished emotional output
- Alogia — poverty of speech (reduced quantity and/or content)
- Why? Same frontal hypofunction → reduced drive to communicate
Avolition-Apathy (AA):
- Anhedonia — reduced capacity to experience pleasure
- Why? Dopamine in mesolimbic reward pathway is dysregulated; mesocortical hypofunction also impairs anticipatory pleasure
- Avolition — reduced motivation and goal-directed behaviour
- Why? Frontal-striatal circuit dysfunction
- Asociality — reduced social drive, social withdrawal
- Why? Combination of reduced motivation, impaired social cognition, and possibly learnt behaviour (social interactions become aversive due to paranoia or past negative experiences)
Primary vs Secondary Negative Symptoms
Primary negative symptoms are a core feature of schizophrenia — very resistant to antipsychotic treatment and closely related to functional outcome [2].
Secondary negative symptoms look identical but are caused by other factors [2]:
- Depression (low mood → social withdrawal, anhedonia)
- Antipsychotics (D2 blockade in mesocortical pathway → flattened affect, avolition)
- Social deprivation (institutional environment)
- Positive symptoms (paranoia → social avoidance)
Always try to distinguish them clinically because secondary causes are potentially treatable!
Deficit syndrome: patients with prominent primary negative symptoms represent a distinct subgroup with extremely poor prognosis and few achieving recovery [2].
Disorganized thinking (formal thought disorder) [2]:
- Tangentiality — answers wander away from the point
- Loosening of associations (derailment) — ideas shift between unrelated topics
- Word salad (incoherence) — speech is incomprehensible
- Neologisms — inventing new words
- Why? Prefrontal cortex dysfunction → impaired executive control over semantic associations; possibly related to GABA interneuron dysfunction in cortical circuits
Disorganized behaviour [2]:
- Unpredictable, bizarre, or inappropriate behaviour
- Difficulty with goal-directed activities
- Inappropriate affect (laughing at sad news)
- Depression — very common in schizophrenia (up to 80% during acute episodes); strongest predictor of suicide in early illness [2]
- Anxiety
- Mania/hypomania — if prominent, consider schizoaffective disorder or bipolar with psychosis
- Impaired attention, working memory, processing speed, executive function, verbal learning
- Emerge in the prodromal period [1] — often preceding frank psychosis by years
- Closely correlated with functional outcome — more predictive than positive symptoms
- Why? Prefrontal cortex hypofunction (mesocortical hypodopaminergia) + disrupted fronto-parietal connectivity
- Catatonia: spectrum from stupor (mutism, immobility, waxy flexibility) to excitement (purposeless motor agitation)
- Neurological soft signs: subtle abnormalities in coordination, sensory integration, sequencing of complex motor acts [1]
- Present premorbidly → supports neurodevelopmental hypothesis
| Domain | Signs | Pathophysiological Basis |
|---|---|---|
| Appearance | Self-neglect, bizarre dress, poor hygiene | Negative symptoms (avolition) + disorganization |
| Behaviour | Psychomotor agitation/retardation, stereotypies, mannerisms, catatonic features, responding to hallucinations (talking to self, looking around, covering ears) | Motor symptoms; response to internal stimuli |
| Speech | Poverty of speech (alogia), pressure of speech (mania), derailment, tangentiality, neologisms, word salad | Formal thought disorder |
| Affect | Flat/blunted (negative symptoms), incongruent (disorganization), perplexed (ATPD), elated/irritable (mania) | Pathway-specific |
| Thought content | Delusions (as above), suicidal/homicidal ideation | — |
| Perception | Evidence of hallucinations (behavioural cues) | — |
| Cognition | Impaired attention, disorientation (if organic cause), poor abstract reasoning | Frontal dysfunction (functional psychosis) vs diffuse cortical dysfunction (organic) |
| Insight | Partial or absent | Core feature of psychosis; related to prefrontal dysfunction and anosognosia |
Red Flags for Organic (Secondary) Psychosis
When assessing a patient with psychotic symptoms, certain features should make you strongly suspect an organic cause:
- Age of onset > 40 years (new-onset psychosis in elderly → think delirium, dementia, tumour)
- Visual hallucinations (especially vivid, formed) → delirium, Lewy body dementia, substance use
- Fluctuating consciousness/clouded sensorium
- Disorientation (to time, place, person)
- Abnormal vital signs (fever, tachycardia, hypertension)
- New neurological signs (focal deficits, seizures)
- Acute onset in a previously well individual
- History of substance use or recent medication changes
- No psychiatric history or family history
Always rule out organic causes first with: bloods (FBC, U&E, LFT, TFT, glucose, Ca²⁺, B12/folate, syphilis, ESR/CRP), urine drug screen, ECG, CT/MRI brain, and consider EEG and lumbar puncture if indicated [2].
- Cardinal symptoms of ICD-11 depression: depressed mood or diminished interest in activities occurring most of the day, nearly every day, for at least two weeks [4]
- Additional symptoms: difficulty concentrating, feelings of worthlessness or excessive guilt, hopelessness, recurrent suicidal thoughts, appetite/sleep changes, psychomotor agitation/retardation, reduced energy/fatigue [4]
- Psychotic features: mood-congruent delusions (nihilistic, guilt, poverty, somatic), auditory hallucinations (derogatory voices)
Mania with psychotic features [3][6]:
- Core features: elation or irritability, increased energy and activity, ↓need for sleep [6]
- Mood lability, disinhibition, recklessness, grandiosity [6]
- Psychotic features: grandiose delusions, persecutory delusions (secondary to grandiosity — "they're jealous of me"), hallucinations affirming grandiose identity
- Mania with psychosis is frequently misdiagnosed as schizophrenia [6]
Key risk factors for bipolar disorder [3]:
- High income countries (may be due to referral bias)
- Low income, separated, divorced, or widowed
- Low care and overprotective parents, poor attachment relationship, childhood abuse
- Family history of bipolar disorder and schizophrenia (monozygotic concordance 40–70%, lifetime risk in first-degree relatives 5–10%, roughly 7 times higher than general population)
- No gender or ethnic difference [3]
When you encounter a patient with psychotic symptoms, think systematically:
Psychiatric vs Medical Psychosis: Clinical Guidance
The distinction between primary (psychiatric) and secondary (medical) psychosis is one of the most important clinical decisions [2]:
| Feature | Psychiatric Psychosis | Medical/Organic Psychosis |
|---|---|---|
| Age of onset | Young adult (15–35) | Any age; suspect if > 40 |
| Consciousness | Clear | Often clouded/fluctuating |
| Orientation | Intact | Impaired |
| Hallucinations | Predominantly auditory | Often visual |
| Delusions | Complex, systematised | Poorly formed, fleeting |
| Cognition | Relatively preserved (early) | Impaired |
| Vital signs | Normal | Often abnormal |
| Psychiatric history/FHx | Often present | Often absent |
| Neurological signs | Absent (except soft signs) | May be present |
Rule: Always exclude organic causes first, especially in first-episode psychosis, elderly patients, and atypical presentations.
For schizophrenia specifically [2]:
- Course: highly heterogeneous, usually chronic and relapsing-remitting
- 30% treatment-resistant, 20% remission, 10% suicide, > 50% poor outcome
- It is postulated that active psychosis is neurotoxic and delayed treatment leads to irreversible neurological deterioration → this is the rationale for minimising duration of untreated psychosis (DUP)
Poor prognostic factors [2]:
| Patient Factors | Disease Factors | Other Factors |
|---|---|---|
| Poor premorbid adjustment | Insidious onset, not related to stress | High EE of caregivers |
| Male gender | Prolonged DUP | Comorbid substance abuse |
| Single | Prominent negative and cognitive symptoms | Poor treatment adherence |
| Family history | Hebephrenic subtype | |
| Prominent affective symptoms | ||
| Poor initial treatment response | ||
| Poor insight |
For other psychotic disorders:
- ATPD/Brief psychotic disorder: generally good prognosis with complete recovery
- Schizoaffective: better than schizophrenia, worse than mood disorders
- Delusional disorder: variable; generally stable trajectory, a proportion develop schizophrenia
- Mood disorders with psychosis: prognosis follows the underlying mood disorder but psychotic features generally indicate more severe illness
High Yield Summary
-
Psychosis is a syndrome, not a diagnosis — always identify the underlying cause (schizophrenia, mood disorder, organic, substance).
-
Four cardinal features: delusions, hallucinations, disorganisation, lack of insight.
-
Epidemiology: ~1% lifetime risk for schizophrenia; 2.5% all psychotic disorders in HK; M:F = 1.4:1; onset late adolescence/early adulthood; 10–15 year reduced lifespan.
-
Dopamine hypothesis: mesolimbic hyperdopaminergia → positive symptoms; mesocortical hypodopaminergia → negative/cognitive symptoms. Also involves glutamate (NMDA hypofunction), GABA, serotonin.
-
Neurodevelopmental hypothesis: schizophrenia is a disorder of brain development (not degeneration) — supported by absence of gliosis, premorbid deficits, prenatal risk factors.
-
Stress-vulnerability model: genetic vulnerability + environmental stressors → psychosis.
-
Classification hierarchy: Organic → Mood disorder with psychosis → Schizoaffective → Schizophrenia → Schizophreniform → ATPD → Delusional disorder → Schizotypal.
-
Negative symptoms (5 A's): affect flattening, alogia, anhedonia, avolition, asociality. Primary (core, treatment-resistant) vs secondary (treatable cause).
-
Schneider's FRS (SPECTRA): somatic passivity, passivity phenomena, echo of thought, commentary, thought insertion/withdrawal/broadcasting, delusional perception/reference, 3rd person AH.
-
Always exclude organic psychosis: visual hallucinations, clouded consciousness, disorientation, abnormal vitals, new neuro signs, age > 40 → think medical cause first.
Active Recall - Approach to Psychotic Symptoms
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p2, p4, p14, p15, p16, p20, p21, p22) [2] Senior notes: ryanho-psych.md (sections 6.1, 6.2) [3] Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (p19, p28) [4] Lecture slides: GC 164. I am depressed Mood disorders.pdf (p10, p12) [5] Lecture slides: GC 164. I am depressed Mood disorders.pdf (p11) [6] Senior notes: ryanho-psych.md (section 7.3)
Differential Diagnosis of Psychotic Symptoms
The single most important question when you encounter a psychotic patient is not "What type of psychosis is this?" but rather "Is this primary (psychiatric) or secondary (medical/organic)?" — because missing an organic cause can be fatal, and treating it as a psychiatric condition will not address the underlying pathology [2].
Think of the differential diagnosis as a funnel: you first exclude the most dangerous and reversible causes (organic), then work through psychiatric causes systematically by asking about mood, duration, and symptom profile.
The Logic of This Funnel
Each step answers a specific clinical question:
- Organic? → Safety first. Exclude medical/substance causes.
- Mood dominates? → If yes, this is a mood disorder with psychotic features (or schizoaffective if psychosis outlasts the mood episode).
- How long? → Duration separates ATPD/brief psychotic disorder (< 1 month), schizophreniform (1–6 months), and schizophrenia (≥ 6 months).
- Encapsulated delusion only? → Delusional disorder is a distinct entity with isolated, non-bizarre, systematised delusion and near-normal functioning otherwise.
Category 1: Secondary (Organic / Medical) Psychosis
This must always be considered and excluded first [2][7]. The mnemonic for why: organic psychosis is reversible if treated and lethal if missed.
| Feature | Details | Why it mimics psychosis |
|---|---|---|
| Core | Acute onset, fluctuating consciousness, inattention, disorientation | Vivid hallucinations (often visual), delusions, agitation, and disorganised behaviour can closely mimic a primary psychotic disorder [7] |
| Key differentiators | Clouded sensorium, impaired attention (cannot serial-7, cannot spell WORLD backwards), disorientation to time/place/person, abnormal vital signs, acute medical precipitant identifiable | In primary psychosis, consciousness is clear and orientation is intact (unless very late-stage) [2] |
| Common causes | Infection (UTI, pneumonia), metabolic (electrolytes, glucose, hepatic/renal failure), drugs (anticholinergics, opioids, steroids, benzodiazepine withdrawal), post-operative, hypoxia | — |
Why does delirium cause psychotic symptoms? Widespread cortical and subcortical dysfunction from metabolic/toxic insults disrupts normal neurotransmitter signalling — particularly acetylcholine deficiency and dopamine excess — producing hallucinations (especially visual, because the visual cortex is highly metabolically active and vulnerable), delusions, and behavioural disorganisation [7].
| Substance | Mechanism | Clinical clues |
|---|---|---|
| Cannabis | THC agonises CB1 receptors → increases mesolimbic dopamine release | Dose-related; high-potency strains; onset temporally related to use; paranoid ideation, AH |
| Amphetamines / methamphetamine | Directly releases dopamine and blocks reuptake → massive dopamine surge in mesolimbic pathway | Persecutory delusions, tactile hallucinations ("formication" — feeling of bugs under skin), agitation, dilated pupils, tachycardia |
| Cocaine | Blocks dopamine transporter → ↑synaptic dopamine | Similar to amphetamines; shorter duration; associated with crack cocaine use |
| Ketamine / PCP | NMDA receptor antagonists → mimics the glutamate hypofunction model of schizophrenia | Can produce full spectrum: positive symptoms, negative symptoms, disorganisation, cognitive deficits [2] |
| LSD / psilocybin | 5-HT2A receptor agonism → visual hallucinations, perceptual distortions [2] | Predominantly visual and perceptual disturbances; consciousness usually preserved |
| Alcohol withdrawal | GABA withdrawal + glutamate rebound → CNS hyperexcitability | Delirium tremens: visual hallucinations (classically small animals), tremor, autonomic instability, seizures |
| Steroids | HPA axis disruption, direct CNS effects | Steroids, L-dopa, stimulants, antidepressants, ECT (in those with bipolar spectrum disorder) can cause manic symptoms [8] |
Key differentiating principle [2][7]: substance-induced psychosis should ↓ after admission (when access to substances is removed) and resolve within days to weeks of cessation. If psychosis persists > 1 month after substance clearance, consider a primary psychotic disorder that was unmasked by the substance.
Always obtain a urine toxicology screen in first-episode psychosis [2].
This is a broad category. The key is to think neurological, endocrine, metabolic, autoimmune, and infective:
| Category | Conditions | Why they cause psychosis |
|---|---|---|
| Neurological | Temporal lobe epilepsy (TLE), brain tumours (especially frontal/temporal), head injury, encephalitis (including anti-NMDA receptor encephalitis), dementia (especially Lewy body dementia), Huntington's disease, HIV encephalopathy, neurosyphilis | Disruption of cortical circuits involved in reality testing; temporal lobe is critical for auditory processing and memory — lesions here can produce AH and complex delusions |
| Endocrine | Hyperthyroidism, Cushing's syndrome [8], Addison's disease, hyperparathyroidism (↑Ca²⁺), pheochromocytoma | Thyroid hormones modulate monoamine neurotransmission; cortisol excess (Cushing's) affects hippocampal and prefrontal function |
| Metabolic | Hypo/hyperglycaemia, hepatic encephalopathy, uraemia, Wilson's disease, acute intermittent porphyria, B12/folate deficiency | Global metabolic derangement → diffuse cortical dysfunction → delirium with psychotic features |
| Autoimmune | SLE cerebritis, anti-NMDA receptor encephalitis | Anti-NMDA receptor encephalitis is particularly important — young woman with psychosis + seizures + movement disorder + autonomic instability → think this diagnosis; antibodies against NMDA receptors mimic the glutamate hypofunction model of schizophrenia |
| Infective | HIV, neurosyphilis, herpes simplex encephalitis, Toxoplasma gondii | Direct neuronal invasion and/or immune-mediated damage |
Anti-NMDA Receptor Encephalitis
This is a commonly tested "great mimicker." A young woman (often with an ovarian teratoma) presents with what looks like acute-onset psychosis — psychiatric symptoms predominate initially. But then she develops seizures, movement disorders (orofacial dyskinesias), autonomic instability, and reduced consciousness. The antibodies target NMDA receptors, literally creating the NMDA hypofunction state that the glutamate hypothesis proposes as a mechanism of schizophrenia. Always consider this in young women with first-episode psychosis, especially if atypical features develop — lumbar puncture and anti-NMDA receptor antibodies are diagnostic; treatment is immunotherapy, not antipsychotics.
Frontal lobe lesions deserve special mention [8]: they can cause extreme social disinhibition without gross mood disturbance → mimics mania. Consider especially in middle-aged or older patients with expansive behaviour but no past history of affective disorder. In younger patients, consider HIV infection and head injury [6].
Investigations to exclude organic causes [2]:
- Bloods: FBC, U&E, LFT, TFT, glucose, Ca²⁺, B12/folate, syphilis serology, ESR/CRP
- ECG: long QT (relevant to lithium, TCA, some antipsychotics)
- CT/MRI: head injury, space-occupying lesion, neurological conditions
- EEG: for epilepsy (especially temporal lobe)
- Urine drug screen
- Consider: lumbar puncture (encephalitis, autoimmune), HIV serology, copper/ceruloplasmin (Wilson's)
Category 2: Primary Psychotic Disorders (Non-Affective)
These are the schizophrenia-spectrum and other non-affective psychoses [1].
The "prototypical" psychotic disorder. Distinguishing features [1][2]:
- Prominent psychotic symptoms lasting at least 1 month affecting functioning
- DSM-5 requires ≥6 months of disturbance (including prodromal/residual periods) in addition to ≥1 month of active psychosis
- Schneider's first-rank symptoms (FRS), when present, are highly suggestive — but literature showed that FRS are not specific to schizophrenia and with minimal prognostic predictive value; nonetheless, FRS are still widely applied and emphasised in current classifications [1]
- Content of delusions/hallucinations is often bizarre in theme ("un-understandable" per Jaspers) [1]
- The most common positive symptoms in schizophrenia and related psychoses include delusion of reference and persecution, and auditory verbal hallucination (AVH) [1]
- Mood disturbance, if any, is not concurrent with psychosis or is relatively minor [2]
- Negative symptoms are a core feature and a key determinant of functional outcome — represent an unmet therapeutic need, not responsive to antipsychotic treatment [1]
- Six symptom dimensions: positive symptoms, negative symptoms, disorganisation (formal thought disorder), affective symptoms (depression/mania), motor signs (catatonia), cognitive impairment [1]
Historical subtypes (Bleuler) — no longer included in DSM-5 but useful clinically [1]:
- Paranoid schizophrenia: prominent positive symptoms
- Hebephrenic (disorganised): younger age of onset, prominent thought disorder / incongruous affect, poor prognosis
- Catatonic: constellation of specific motor signs e.g. posturing, waxy flexibility, mutism
- Simple: lack of positive symptoms, gradual functional decline, prominent negative symptoms
- Catatonia: not specific to schizophrenia, currently as a diagnostic specifier in DSM-5 [1]
Bleuler's fundamental symptoms [1]: loosening of association, affect flattening, autism, ambivalence — these were what Bleuler considered the core ("fundamental") features, as opposed to Schneider's FRS which he considered "accessory."
DSM-5 Criteria (simplified) [2]:
A. ≥2 of: (1) Delusions, (2) Hallucinations, (3) Disorganised speech, (4) Grossly disorganised/catatonic behaviour, (5) Negative symptoms — at least one must be (1), (2), or (3), each present for ≥1 month B. Functional impairment C. ≥6 months of continuous disturbance (including at least 1 month meeting Criterion A) D. Not better explained by schizoaffective or mood disorder with psychosis E. Not due to substance or medical condition F. If ASD present, prominent delusions/hallucinations for ≥1 month needed
- Concurrent schizophrenic and mood symptoms are equally prominent (fulfilling a major mood episode e.g. manic or depressive episode) [1]
- Delusions/hallucinations for ≥2 weeks outside major mood episode (DSM-5) — this is the key criterion that separates it from mood disorder with psychotic features [2]
- Meet mood episode criteria for majority of symptomatic duration
- Functional impact less marked than schizophrenia [2]
- Prognosis better than schizophrenia (negative symptoms rarely develop) but worse than mood disorders [2]
- The validity of this as a distinct entity is questionable — it is neither genetically nor neurobiologically separated from schizophrenia or mood disorders [2]
How to distinguish from schizophrenia: In schizophrenia, mood disturbances are relatively minor and not concurrent with the main psychotic phase. In schizoaffective, mood and psychosis are equally prominent and psychosis persists even when mood normalises.
How to distinguish from mood disorder with psychosis: In mood disorder with psychosis, psychosis occurs only during mood episodes. In schizoaffective, psychosis persists for ≥2 weeks outside mood episodes.
These represent psychotic episodes that don't (yet) meet duration criteria for schizophrenia [1][2]:
| Diagnosis | Duration | Key Features |
|---|---|---|
| ATPD (ICD-10/11) | Onset ≤2 weeks | Acute onset, complete remission, brief period (1–3 months) [1] |
| Brief psychotic disorder (DSM-5) | < 1 month | Often stress-precipitated |
| Schizophreniform disorder (DSM-5) | 1–6 months | Essentially "schizophrenia lite" — same symptoms, shorter duration |
Polymorphic features (~cycloid psychosis): rapidly changing clinical pictures, prominent fluctuating mood state, perplexity [1] — the clinical picture shifts dramatically from day to day, which is unlike the more stable symptom profile of established schizophrenia.
Why is this important? Because prognosis is generally much better than schizophrenia — many patients recover completely. However, a proportion will go on to develop schizophrenia, so follow-up is essential.
- Systematised, likely single-theme delusion, non-bizarre in nature (classic definition) [1]
- No or non-prominent hallucination [1]
- Minimal negative symptoms, reported of having better functioning [1]
- Over-represented by women and adult-onset [1]
- Relatively rare (lifetime risk 0.05–0.1%, median onset age 46 years) [2]
- Encapsulated: behaviour unrelated to the delusion is often normal [2]
- Themes: persecutory (commonest), erotomania, jealous, somatic, grandiose [2]
- Presence of classical schizophrenic delusions rules out this diagnosis [2]
- A proportion goes on to develop full-blown schizophrenia [2]
Why is it encapsulated? Because the delusion is a single, circumscribed belief system that doesn't "leak" into all areas of functioning. The patient's reality testing is intact in all domains except the specific delusional theme. Think of it as a "walled-off" area of abnormal belief in an otherwise normal mind — hence the older term "paranoia."
- Part of the schizophrenia-spectrum [1][2]
- Attenuated (sub-threshold) versions of all schizophrenia symptom domains [2]:
- Cognitive distortions (odd beliefs, magical thinking) — attenuated delusions
- Perceptual distortions (illusions, "sixth sense") — attenuated hallucinations
- Odd behaviour, eccentric appearance — attenuated disorganisation
- Social isolation, few close friends — attenuated negative symptoms
- Patient has never met criteria for schizophrenia throughout entire life [2]
- Considered personality disorder in DSM-5, schizophrenia-like disorder in ICD-10 [2]
- ↑Risk of evolving into overt schizophrenia
- D/dx from schizoid personality disorder: schizoid has similar social isolation but no cognitive/perceptual distortions [2]
Category 3: Mood Disorders with Psychotic Features
The key principle: mood disturbances dominate the clinical picture, and psychosis is mood-congruent [2].
- Current depressive episode (≥2 weeks, meeting criteria) with psychotic features [2][9]
- Psychotic features are mood-congruent: nihilistic delusions ("my organs are rotting," "I have committed an unforgivable sin"), auditory hallucinations with derogatory/critical content, delusions of guilt, poverty, or deserved punishment [2]
- Graded as severe with psychotic symptoms (ICD-10: F3x.3) [9]
- Why does severe depression cause psychosis? When the monoamine deficit (serotonin, norepinephrine, dopamine) becomes severe enough, the downstream effect on mesolimbic and mesocortical circuits can produce frank psychotic symptoms. Additionally, the HPA axis hyperactivation (cortisol excess) in severe depression has neurotoxic effects on the hippocampus and prefrontal cortex, further impairing reality testing.
- Manic episode with psychotic symptoms — indicates severe mania [8]
- Presence of psychotic symptoms (mood-congruent or mood-incongruent) [8]
- Psychotic features are usually mood-congruent: grandiose delusions (believe one is a religious prophet), persecutory delusions (especially when mood is irritable — "they are conspiring against me because of my supreme status"), delusions of reference, passivity [6]
- Note: 10–20% of manic patients have first-rank symptoms but these are usually fleeting [6]
- Hallucinations usually mood-congruent: voices speaking about special powers, visions with religious content [6]
Mania vs Schizophrenia: The Most Difficult Distinction
Manic episode with psychotic symptoms is frequently misdiagnosed as schizophrenia [8]. This matters enormously because treatment is fundamentally different (mood stabilisers vs antipsychotics alone) and misdiagnosis delays correct treatment by 5–7 years on average [8].
Key distinguishing features (from the DDx table) [6]:
| Feature | Mania with Psychosis | Schizophrenia |
|---|---|---|
| Psychotic symptoms | Usually mood-congruent, change quickly in content, seldom outlast mood disruption | Mood-incongruent, bizarre, with passivity/thought alienation |
| Formal thought disorder | Circumstantiality, tangentiality, flight of ideas (logical links preserved) | Loosening of association, neologism, thought blocking |
| Speech | Pressured, difficult to interrupt | More hesitant/halting |
| Biological | ↓Need for sleep (feel energetic), hyperactive | Less ↓need for sleep, less hyperactive |
| Motor | Predominantly agitation | May have catatonia or negative symptoms in addition |
| Course | Episodic with inter-episode recovery | Usually chronic/relapsing |
| FRS | If present, fleeting (10–20%) | More persistent and prominent |
Listed here again because schizoaffective sits at the boundary between mood disorders and schizophrenia. The distinguishing principle:
- Mood disorder with psychosis: psychosis occurs only during mood episodes
- Schizoaffective: psychosis persists ≥2 weeks outside mood episodes, but mood episodes are prominent
- Schizophrenia: mood disturbance is minor or absent
These don't produce "true" psychosis in the strict sense but can be mistaken for it:
| Condition | How it mimics psychosis | Key differentiator |
|---|---|---|
| PTSD / acute stress disorder | Flashbacks (can resemble hallucinations), hypervigilance (can resemble paranoia), dissociative symptoms | Clear temporal relationship to trauma; flashbacks are re-experiencing of actual events, not novel perceptions; consciousness is not clouded [7] |
| OCD | Severe obsessions can approach delusional intensity (overvalued ideas); patients may report "hearing" intrusive thoughts | Patient typically recognises thoughts as their own (ego-dystonic); reality testing preserved (though may be poor in severe OCD with poor insight) |
| Borderline personality disorder | Transient, stress-related paranoid ideation or dissociative symptoms (DSM-5 criterion 9 for BPD); prominent affective instability mimics rapid cycling bipolar [6] | Symptoms are brief (hours, not days/weeks), triggered by interpersonal stress, and resolve when stressor passes; no classic mania features (↑energy, grandiosity, ↓need for sleep) [6]; mood shifts over hours/days (not weeks) |
| ADHD | ↓Attention, difficulty with task completion, ↑energy, disinhibited behaviour mimic hypomania [6][8] | Should NOT have ↑self-esteem, grandiosity, flight of ideas, ↓need for sleep; course is chronic (trait-like) rather than episodic [6] |
| Severe anxiety disorders | Anxiety secondary to delusions in schizophrenia vs primary anxiety disorder | Note the theme/focus of anxiety: fear of poisoning → paranoid schizophrenia; obsessional thoughts → OCD; worry about weight → eating disorder; feelings of worthlessness → depression [7] |
| Dissociative disorders | Altered perception of reality, depersonalisation/derealisation | Reality testing is preserved; patient describes experiences as "unreal" (they know something is off) |
Differential Diagnosis of Manic Episode
Differential diagnosis of manic episode (from lecture slides) [8]:
- Depressive disorder with irritability and anxious distress
- Psychotic disorder or schizoaffective disorder
- Substance/medication-induced/medical conditions
- Attention deficit and hyperactivity disorder
- Personality disorder with prominent irritability
Drugs and medical conditions that cause manic symptoms [8]:
- Steroids, L-dopa, stimulants, antidepressants, ECT (in those with bipolar spectrum disorder)
- Cocaine, amphetamine
- Frontal lobe lesion, hyperthyroidism, Cushing's syndrome
It is important to recognise that:
- Psychotic-like experiences (hearing one's name called, fleeting paranoid thoughts, sleep-onset hallucinations) are common in the general population (~5–8%) and do not constitute a disorder
- Grief-related hallucinations (hearing the deceased's voice) are common and normal in bereavement
- Cultural/religious experiences (visions, speaking in tongues) must be assessed in context — they are not psychosis if consistent with the person's cultural/religious background (remember: delusions are "out of keeping with social and cultural background")
| Diagnosis | Duration | Mood | Hallucination Type | Delusion Character | Functioning | Consciousness |
|---|---|---|---|---|---|---|
| Organic psychosis | Variable | Variable | Often visual | Poorly formed, fleeting | Impaired | Clouded |
| Substance-induced | Resolves with cessation | Variable | Variable | Variable | Impaired during use | May be clouded |
| Schizophrenia | ≥6 months | Minor/absent | Auditory (FRS) | Bizarre, systematised | Significantly impaired | Clear |
| Schizoaffective | Variable | Equally prominent | Auditory | Variable | Less impaired than SZ | Clear |
| ATPD/Brief psychotic | < 1 month | Fluctuating | Variable | Polymorphic | Acutely impaired | Clear |
| Delusional disorder | ≥1 month (DSM-5) | Normal | Minimal/absent | Non-bizarre, single-theme | Relatively preserved | Clear |
| Psychotic depression | ≥2 weeks | Depressed | Derogatory voices | Mood-congruent (nihilistic, guilt) | Impaired | Clear |
| Mania with psychosis | ≥1 week | Elated/irritable | Mood-congruent | Mood-congruent (grandiose) | Impaired | Clear |
| Schizotypal PD | ≥2 years (trait) | Constricted | Attenuated (illusions) | Attenuated (odd beliefs) | Mildly impaired | Clear |
When presented with a case, systematically work through this checklist:
- Exclude organic causes: Age > 40? Visual hallucinations? Fluctuating consciousness? Abnormal vitals? New neuro signs? Substance history? → Investigate accordingly
- Assess mood: Is there a prominent depressive or manic episode? Is the psychosis mood-congruent? Does it persist outside mood episodes?
- Duration: < 1 month → ATPD/brief psychotic disorder. 1–6 months → schizophreniform. ≥6 months → schizophrenia
- Delusion quality: Isolated, non-bizarre, encapsulated with preserved functioning → delusional disorder. Bizarre, multiple, with negative symptoms → schizophrenia
- Formulate differentials: List "For" and "Against" points for each diagnosis (as in the psychiatric formulation framework [2])
Example formulation approach [2]:
| Differential | For | Against |
|---|---|---|
| Schizophrenia | Symptoms > 1 month; FRS present; bizarre delusions; functional decline | — |
| Schizoaffective disorder | Typical schizophrenic symptoms present | No prominent concurrent mood episode |
| Mood disorder with psychotic features | — | Mood not primarily lowered/elevated; mood-incongruent psychosis |
| Substance-induced psychosis | — | No evidence of substance use; symptoms persistent |
| Organic psychosis | — | No medical illness; normal physical examination |
High Yield Summary — Differential Diagnosis of Psychotic Symptoms
-
Always exclude organic causes first — especially delirium, substance-induced psychosis, and medical conditions (TFT, glucose, B12, syphilis, neuroimaging).
-
Visual hallucinations + clouded consciousness + disorientation = think organic, not primary psychosis.
-
Mood-congruent psychosis that occurs only during mood episodes = mood disorder with psychotic features. Psychosis persisting ≥2 weeks outside mood episodes = schizoaffective.
-
Duration hierarchy: ATPD (< 1 month) → schizophreniform (1–6 months) → schizophrenia (≥ 6 months).
-
Delusional disorder: isolated, single-theme, non-bizarre delusion; minimal other symptoms; preserved functioning.
-
Mania with psychosis is commonly misdiagnosed as schizophrenia — look for episodic course, mood-congruent delusions, flight of ideas (logical links preserved), pressured speech, ↓need for sleep.
-
Anti-NMDA receptor encephalitis is the great mimicker in young women with new-onset psychosis — always consider if atypical features develop (seizures, movement disorder, autonomic instability).
-
FRS are not pathognomonic for schizophrenia — they occur in mania (10–20%, fleeting) and other psychoses. But they remain widely applied in classification.
Active Recall - Differential Diagnosis of Psychotic Symptoms
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p2, p7, p8, p9, p10, p22) [2] Senior notes: ryanho-psych.md (sections 6.1, 6.2, 2.2.4) [6] Senior notes: ryanho-psych.md (sections 7.3, 7.1.2) [7] Senior notes: ryanho-psych.md (sections 4.1, 8.4.1) [8] Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (p10, p11, p12, p18) [9] Senior notes: ryanho-psych.md (section 7.1.1)
Diagnostic Criteria for Psychotic Disorders
Diagnosis in psychiatry is fundamentally clinical — there is no blood test or imaging study that confirms "schizophrenia" or "schizoaffective disorder." Instead, we rely on pattern recognition: a specific cluster of symptoms, present for a defined duration, causing functional impairment, after excluding organic and substance-related causes. This is why diagnostic criteria exist — they provide standardised, reliable thresholds for what "counts" as a given disorder [2][10].
Two classification systems are in widespread use:
- ICD-10/11 (WHO) — used in Hong Kong's public hospital system (HA coding)
- DSM-5 (APA) — widely used in research and clinical practice globally
The key philosophical point: diagnostic criteria usually consist of [10]:
- Cluster of symptoms — core (discriminating) symptoms present in the defined disorder but seldom in others, plus associated (characteristic) symptoms
- Minimal duration of symptoms
- Distress or impairment in functioning
- Exclusion criteria (organic causes, substance use, other psychiatric disorders)
There is also a hierarchy of diagnosis [10]: when symptoms can be explained by multiple diagnoses, the higher-order diagnosis takes precedence (organic > psychotic > mood > anxiety > personality), because treatment of the higher-order disorder often leads to resolution of symptoms at the lower order, but not vice versa.
1. Diagnostic Criteria for Schizophrenia
This is the most important set of criteria to know for exams. Both ICD-10 and DSM-5 criteria are presented side-by-side because they differ in important ways.
A. Two or more of the following, each present for a significant portion of time during a 1-month period (or less if successfully treated). At least one must be (1), (2), or (3):
- Delusions
- Hallucinations
- Disorganised speech (e.g., frequent derailment or incoherence)
- Grossly disorganised or catatonic behaviour
- Negative symptoms (i.e., diminished emotional expression or avolition)
B. Impaired level of functioning in one or more domain (e.g., work, relationships) for a significant portion of time since onset. In childhood/adolescence onset, failure to achieve expected functioning.
C. Continuous signs of disturbance persist for at least 6 months. This 6-month period must include at least 1 month of symptoms meeting Criterion A (active-phase symptoms).
D. Not better explained by schizoaffective disorder or mood disorder with psychotic features.
E. Not attributable to substance or medical condition.
F. If there is a history of autism spectrum disorder, the additional diagnosis of schizophrenia requires prominent delusions or hallucinations for ≥1 month, in addition to other required symptoms.
Symptoms must be clearly present for most of the time during ≥1 month:
At least ONE of major symptoms (a–d, which map to Schneider's FRS):
- (a) Thought echo, thought insertion or withdrawal, and thought broadcasting (delusions of thought alienation)
- (b) Delusions of control, influence, or passivity clearly referred to body/limb movements or specific thoughts, actions, sensations; delusional perception
- (c) Hallucinatory voices giving a running commentary, or discussing the patient among themselves, or other hallucinatory voices coming from some part of the body
- (d) Persistent delusions that are culturally inappropriate and completely impossible (i.e., bizarre)
OR at least TWO of lesser symptoms (e–i):
- (e) Persistent hallucinations in any modality, accompanied by fleeting delusions or persistent overvalued ideas
- (f) Breaks or interpolations in thought → incoherence, irrelevant speech, neologisms
- (g) Catatonic behaviour (excitement, posturing, waxy flexibility, negativism, mutism, stupor)
- (h) Negative symptoms (marked apathy, paucity of speech, blunting/incongruity of emotional responses → social withdrawal) — must be clear these are not due to depression or neuroleptic medication
- (i) Significant and consistent change in overall quality of personal behaviour (loss of interest, aimlessness, idleness, self-absorbed attitude, social withdrawal)
DSM-5 vs ICD-10: Key Differences for Exams
| Feature | ICD-10 | DSM-5 |
|---|---|---|
| Duration | 1 month of symptoms | 1 month of active symptoms + 6 months total disturbance |
| FRS emphasis | Major symptoms (a–d) are essentially FRS — only ONE needed | FRS not given special weighting; need ≥2 of any 5 criteria with ≥1 being delusions, hallucinations, or disorganised speech |
| Minimum symptoms | 1 major OR 2 lesser | 2 of 5, with at least 1 from top 3 |
| Functional impairment | Implied but not an explicit criterion | Explicit criterion (B) |
| Subtypes | Retains subtypes (paranoid, hebephrenic, catatonic, simple) | Subtype classification no longer included in DSM-5 [1] |
The practical implication: ICD-10 gives more weight to FRS and requires a shorter duration (1 month vs 6 months). DSM-5 is more conservative — the 6-month requirement means some patients diagnosed with schizophrenia under ICD-10 would only qualify for "schizophreniform disorder" under DSM-5.
Catatonia: not specific to schizophrenia, currently a diagnostic specifier in DSM-5 [1] — meaning it can be applied to any condition (schizophrenia, mood disorders, medical conditions).
A. Major mood episode (manic or depressive) concurrent with active-phase symptoms of schizophrenia (Criterion A of schizophrenia)
B. Delusions or hallucinations for ≥2 weeks in the absence of a major mood episode during the lifetime duration of the illness
C. Symptoms meeting criteria for a major mood episode are present for the majority of the total duration of the active and residual portions of the illness
D. Not attributable to substance or medical condition
Why does Criterion B matter? It is the defining criterion that separates schizoaffective from mood disorder with psychotic features. If psychosis ONLY occurs during mood episodes, the diagnosis is mood disorder with psychosis. If psychosis persists for ≥2 weeks without any mood episode, then there's an independent psychotic process — hence schizoaffective.
Why does Criterion C matter? It separates schizoaffective from schizophrenia. In schizophrenia, mood symptoms are relatively minor. In schizoaffective, mood episodes must be present for the majority of the illness duration — if mood symptoms are only brief, the diagnosis is schizophrenia with comorbid mood symptoms, not schizoaffective.
These exist because not every psychotic episode becomes schizophrenia. The key differentiator is duration [1][2]:
| Diagnosis | Classification | Duration Criteria | Key Features |
|---|---|---|---|
| Brief psychotic disorder | DSM-5 | ≥1 psychotic symptom for ≥1 day but < 1 month with eventual return to premorbid functioning | May be precipitated by acute stress |
| Acute and transient psychotic disorder (ATPD) | ICD-10/11 | Acute onset (≤2 weeks), complete recovery within 2–3 months | Polymorphic features (~cycloid psychosis): rapidly changing clinical pictures, prominent fluctuating mood state, perplexity [1] |
| Schizophreniform disorder | DSM-5 | Meeting schizophrenia Criterion A for > 1 month but < 6 months | Essentially "early schizophrenia" — if symptoms persist beyond 6 months, reclassify as schizophrenia |
Why do these entities exist? Because prognosis is fundamentally different. Many patients with brief psychotic episodes recover completely and never relapse. Labelling them as "schizophrenia" would be prognostically inaccurate and potentially harmful (stigma, unnecessary long-term treatment). However, a proportion will go on to develop schizophrenia, so follow-up is essential.
| Feature | ICD-10 | DSM-5 |
|---|---|---|
| Duration | ≥3 months | ≥1 month |
| Delusion type | Non-bizarre, systematised, single-theme [1] | Non-bizarre (with "bizarre" specifier available) |
| Other psychotic symptoms | No or non-prominent hallucination [1]; minimal negative symptoms | Apart from the direct impact of delusions, functioning is not markedly impaired |
| Exclusion | Presence of classical schizophrenic delusions rules out this diagnosis [2] | Criterion A for schizophrenia has never been met (apart from delusions) |
5. Diagnostic Criteria for Mood Episodes with Psychotic Features
A distinct period of elevated, expansive, or irritable mood and increased goal-directed activity lasting at least 1 week (or any duration if hospitalisation required)
Three or more of (4 if mood is only irritable):
- Inflated self-esteem or grandiosity
- Decreased need for sleep
- Pressured speech
- Flight of ideas / racing thoughts
- Distractibility
- Increased goal-directed activity (socially, at work/school, or sexually) / psychomotor agitation
- Excessive involvement in pleasurable activities (buying sprees, sexual indiscretions, foolish business investments)
Marked impairment in functioning, observable by others, to necessitate hospitalisation, or there are psychotic symptoms
Not due to alcohol, substance, or medical conditions [8]
The presence of psychotic features = mania with psychotic features = severe mania requiring hospitalisation [8].
At least 4 days of elevated, expansive, or irritable mood and increased activity or energy
3 or more of manic symptoms (same list as above)
Change in functioning observable by others but NOT severe enough to cause marked impairment, to necessitate hospitalisation, and there are NO psychotic symptoms [8]
Mania vs Hypomania: The Key Distinction
The distinction is one of severity and consequence, not symptom type:
- Hypomania: noticeable change, but the person can still function. No psychotic features, no hospitalisation needed. Duration ≥4 days [8].
- Mania: severe impairment, may require hospitalisation, may have psychotic features. Duration ≥1 week (or any duration if hospitalised) [8].
Hypomanic episodes are often missed by patients and doctors, resulting in delayed diagnosis [8]. This is why bipolar II is commonly misdiagnosed as major depressive disorder and correct diagnosis and treatment is delayed by 5–7 years on average [8].
ICD-10 grades depressive episodes as mild, moderate, severe, and severe with psychotic symptoms (F3x.3) if delusion, hallucination, or depressive stupor is present [9].
DSM-5 uses specifiers: with psychotic features (mood-congruent or mood-incongruent), with catatonia, with peripartum onset, with seasonal pattern, etc. [9]
Understanding the natural history is critical for knowing when to apply each diagnostic criterion [1][2]:
Development and course of schizophrenia [1]:
| Phase | Timing | Features |
|---|---|---|
| Premorbid phase | Childhood | Subtle motor, cognitive, and social deficits (supports neurodevelopmental hypothesis) |
| Prodrome (at-risk mental state, ARMS / clinical high-risk, CHR) | Adolescence and early adulthood | Attenuated psychotic symptoms, functional decline, may herald overt psychosis in 2–3 years or may resolve (no transition to psychosis is also possible) [1][2] |
| First psychotic episode (FEP) | Onset of psychosis | Golden window for intervention → early intervention paradigms [2] |
| Longitudinal course of illness | Variable | Outcomes range from fully recovered to residual deficits [1] |
| Residual schizophrenia | ≥1 year | Chronic negative symptoms preceded by ≥1 prior psychotic episode [2] |
The following algorithm integrates the diagnostic criteria into a practical clinical decision pathway. At each node, you're asking a specific question that corresponds to a specific criterion or exclusion rule:
How to use this algorithm:
-
Red zone (Step 1): Always start here. Exclude organic and substance causes before any psychiatric diagnosis. This corresponds to DSM-5 Criterion E for schizophrenia ("not attributable to substance or medical condition") and is the highest priority in the hierarchy of diagnosis [10].
-
Yellow zone (Step 2): If primary psychiatric, ask about mood. This determines whether you're dealing with a mood disorder with psychosis, schizoaffective disorder, or a non-affective psychosis. Corresponds to DSM-5 Criterion D for schizophrenia ("not better explained by schizoaffective or mood disorder with psychotic features").
-
Green zone (Step 3): Duration separates the brief psychotic disorders from schizophrenia. This corresponds to DSM-5 Criterion C (6-month duration).
-
Blue zone (Step 4): Among chronic psychoses, the pattern of symptoms separates delusional disorder from schizophrenia.
Investigation Modalities
Investigations in psychosis serve three purposes [2][10]:
- Exclude secondary (organic) causes — the most important reason
- Establish baseline before starting medications (especially antipsychotics, lithium)
- Screen for neglect and comorbidities (malnutrition, infections, metabolic syndrome)
There is no investigation that "diagnoses" a primary psychotic disorder. The diagnosis is always clinical.
| Investigation | What You're Looking For | Key Findings and Interpretation | Why |
|---|---|---|---|
| CBC | ↓Hb (anaemia), ↑MCV (alcoholism — macrocytosis from folate deficiency/direct toxicity), ↑WBC (infection as cause of delirium) [2][10] | Anaemia can cause fatigue/cognitive symptoms mimicking negative symptoms; macrocytosis in a young psychotic patient should trigger alcohol/B12 workup | Screen for organic cause + baseline before clozapine (which causes agranulocytosis) |
| Renal function tests (RFT) | U/Cr (uraemic encephalopathy), Ca²⁺ (mood changes/psychosis) [2][10] | ↑Urea/Cr → uraemia → delirium with psychotic features; ↑Ca²⁺ → primary hyperparathyroidism → depression, psychosis, cognitive impairment ("bones, stones, groans, and psychiatric moans") | Organic screen + baseline for lithium (which is renally excreted) |
| Liver function tests (LFT) | Albumin (malnutrition), ↑GGT (alcoholism), liver enzymes, ammonia (hepatic encephalopathy) [2][10] | Hepatic encephalopathy presents with fluctuating consciousness and psychotic features; ↓albumin suggests self-neglect/malnutrition in chronic psychosis | Organic screen + baseline for hepatically metabolised drugs |
| Thyroid function tests (TFT) | Hypo- and hyperthyroidism [2][10] | Hypothyroidism → depression, psychomotor retardation, cognitive slowing (mimics negative symptoms/psychotic depression). Hyperthyroidism → agitation, anxiety, even frank psychosis ("thyroid storm"). Also critical for lithium monitoring (lithium causes hypothyroidism) | Organic screen + baseline |
| Urine drug screen / serum toxicology | Substance-induced psychosis [2][10] | Positive for cannabis, amphetamines, cocaine, opioids, benzodiazepines, ketamine. Essential in first-episode psychosis and any atypical presentation | If positive: substance-induced psychosis is higher in the diagnostic hierarchy |
| Fasting glucose / HbA1c | Baseline metabolic screen [10] | Many 2nd-generation antipsychotics (especially olanzapine, clozapine) cause metabolic syndrome (weight gain, insulin resistance, dyslipidaemia). Also: hypoglycaemia can cause acute confusion with psychotic features | Baseline before antipsychotic initiation + organic screen |
| Fasting lipid profile | Baseline metabolic screen | As above — antipsychotic-related metabolic syndrome | Baseline |
| Investigation | When to Order | Key Findings | Interpretation |
|---|---|---|---|
| B12 / folate | Elderly, vegan/vegetarian, alcoholism, macrocytic anaemia, cognitive impairment [2][10] | ↓B12 → megaloblastic anaemia + subacute combined degeneration of the cord + psychosis and cognitive decline | B12 deficiency is a reversible cause of psychosis and dementia — always check in elderly first-episode psychosis |
| Syphilis serology (VDRL/RPR + confirmatory FTA-ABS) | All first-episode psychosis (especially in Hong Kong where neurosyphilis still occurs), cognitive decline, neurological signs [2][10] | Positive serology + CSF abnormalities → neurosyphilis | Neurosyphilis (general paresis of the insane) classically presents with grandiose delusions, personality change, and progressive dementia — one of the great historical mimickers of psychiatric illness |
| HIV serology | Risk factors, young patient with new-onset psychosis, cognitive decline [2] | HIV encephalopathy can present with psychosis | Direct CNS infection + opportunistic infections |
| ESR / CRP | Suspected autoimmune or infective cause [2][10] | ↑inflammatory markers → consider SLE cerebritis, vasculitis, autoimmune encephalitis | Non-specific but guides further workup |
| ECG | Before starting antipsychotics, lithium, or TCAs [2][10] | Long QT interval → risk of torsades de pointes and sudden cardiac death | Many antipsychotics (especially haloperidol IV, ziprasidone) and lithium, TCAs prolong QT [10]. Baseline ECG is mandatory before initiation. If QTc > 500 ms, avoid QT-prolonging drugs |
| CT / MRI brain | First-episode psychosis (especially atypical), suspected neurological condition, cognitive deficits, age > 40, focal neurological signs [2][10] | Space-occupying lesion (tumour), demyelination (MS), temporal lobe pathology (epilepsy focus), ventriculomegaly, cerebral atrophy | MRI is preferred over CT for detail. In schizophrenia research, ↑ventricular volume and ↓grey matter volume (especially temporal and prefrontal) are seen, but these are NOT diagnostic in clinical practice |
| EEG | Suspected epilepsy (especially temporal lobe epilepsy), fluctuating consciousness, atypical presentations [2][10] | Epileptiform discharges, temporal lobe focus | Temporal lobe epilepsy (TLE) is the epilepsy type most commonly associated with psychosis ("interictal psychosis" or "postictal psychosis") — the temporal lobe is involved in auditory processing and memory |
| Lumbar puncture + CSF analysis | Suspected encephalitis (especially anti-NMDA receptor encephalitis), meningitis, neurosyphilis | CSF pleocytosis, protein elevation, specific antibodies (anti-NMDA-R Ab), oligoclonal bands | Young woman + new-onset psychosis + seizures + movement disorder → anti-NMDA receptor Ab in CSF is diagnostic |
| Autoimmune panel | Suspected autoimmune encephalitis or SLE cerebritis | Anti-NMDA-R Ab, ANA, anti-dsDNA, complement levels | — |
| Copper / ceruloplasmin | Young patient with psychosis + movement disorder + liver disease | ↓Ceruloplasmin, ↑free copper, ↑24h urinary copper | Wilson's disease (hepatolenticular degeneration) — treatable cause of psychosis with extrapyramidal features |
While not "investigations" in the laboratory sense, structured assessments are integral to diagnosis and monitoring:
| Scale | Purpose | Details |
|---|---|---|
| Mood Disorder Questionnaire (MDQ) | Screen for bipolar disorder | Self-report; useful when hypomania is suspected but not clearly reported [6] |
| Hypomania Checklist (HCL-32) | Screen for hypomania | Self-report; hypomanic episodes are often missed by patients and doctors [8] |
| PANSS (Positive and Negative Syndrome Scale) | Quantify symptom severity in schizophrenia | 30-item clinician-rated scale: 7 positive, 7 negative, 16 general psychopathology items |
| BPRS (Brief Psychiatric Rating Scale) | Quick assessment of psychotic symptoms | 18-item clinician-rated scale |
| CGI (Clinical Global Impression) | Global severity and improvement | Clinician-rated; used in clinical trials |
| GAF (Global Assessment of Functioning) | Functional assessment | Score 0–100; required in DSM-IV multiaxial system |
Investigations Are for Exclusion, Not Confirmation
In primary psychotic disorders, all investigations are expected to be normal. You investigate to rule out secondary causes and to establish baseline before treatment. A positive finding on any investigation should make you reconsider whether this is truly a primary psychotic disorder. The diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, etc., is made clinically based on history, mental state examination, and observed course over time — not by any laboratory test or imaging finding [2].
Clozapine-Specific Monitoring
If a patient is started on clozapine (the gold standard for treatment-resistant schizophrenia), additional mandatory monitoring is required:
- Mandatory regular CBC — clozapine can cause agranulocytosis (risk ~1%, usually in first 18 weeks). In Hong Kong, the Clozapine Patient Monitoring Service (CPMS) requires:
- Weekly FBC for first 18 weeks
- Then every 2 weeks for 1 year
- Then monthly for life
- If absolute neutrophil count (ANC) < 1.5 × 10⁹/L → withhold and investigate; < 0.5 × 10⁹/L → discontinue permanently
- Also monitor: fasting glucose, lipids, weight, waist circumference (metabolic syndrome), troponin/CRP if myocarditis suspected (fever + tachycardia + chest pain in first month)
When presented with a patient with psychotic symptoms in an exam:
Step 1: Describe the psychopathology accurately [10]
- Identify the form of symptoms (e.g., auditory hallucination, persecutory delusion, formal thought disorder)
- Form assists in making diagnosis; content is more useful for management [10]
- Note whether features are consistent with Schneider's FRS [1] — while FRS are not specific to schizophrenia and have minimal prognostic predictive value, they are still widely applied and emphasised in current classifications [1]
Step 2: Exclude organic causes (Criterion E/D equivalent)
- List relevant investigations and their expected findings
- State "for/against" organic psychosis
Step 3: Assess mood (Criterion D equivalent)
- Is there a concurrent mood episode meeting criteria for MDE or mania?
- If yes: does psychosis persist outside mood episodes? → determines mood disorder with psychosis vs schizoaffective
Step 4: Assess duration (Criterion C equivalent)
- < 1 month → brief psychotic disorder/ATPD
- 1–6 months → schizophreniform
- ≥ 6 months → schizophrenia
Step 5: Check functional impairment (Criterion B)
Step 6: Formulate with "For" and "Against" for each differential [10]
- Example format:
- "For schizophrenia: symptoms > 6 months, FRS present (3rd person AH, thought insertion), functional decline, no prominent mood episode"
- "Against schizoaffective: no concurrent major mood episode"
- "Against organic: age 22, clear consciousness, no focal signs, normal investigations"
High Yield Summary — Diagnostic Criteria and Investigations
-
DSM-5 schizophrenia: ≥2 of 5 symptoms (at least 1 must be delusions, hallucinations, or disorganised speech), ≥1 month active + ≥6 months total, functional impairment, exclude schizoaffective/mood disorder, exclude organic/substance.
-
ICD-10 schizophrenia: 1 of FRS (a–d) OR 2 of lesser symptoms (e–i), ≥1 month. FRS are given more diagnostic weight in ICD-10 than in DSM-5.
-
Schizoaffective key criterion: psychosis must persist ≥2 weeks OUTSIDE mood episodes (otherwise it's mood disorder with psychosis).
-
Duration hierarchy: Brief psychotic disorder (< 1 month) → Schizophreniform (1–6 months) → Schizophrenia (≥ 6 months).
-
Mania: ≥1 week of elevated/irritable mood + ≥3 symptoms + marked impairment. Hypomania: ≥4 days + ≥3 symptoms + NO marked impairment and NO psychotic features.
-
Investigations are for exclusion (organic causes) and baseline (before medication). No test confirms a primary psychotic disorder.
-
Mandatory first-line: CBC, RFT (+ Ca²⁺), LFT, TFT, fasting glucose/lipids, urine drug screen, ECG.
-
Extended (if red flags): CT/MRI brain, EEG, B12/folate, VDRL, HIV, ESR/CRP, LP, autoimmune antibodies.
-
Hierarchy of diagnosis: organic > psychotic > mood > anxiety > personality — always exclude higher-order causes first.
Active Recall - Diagnostic Criteria and Investigations for Psychosis
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p2, p5, p7, p8, p9, p10, p22) [2] Senior notes: ryanho-psych.md (sections 6.1, 6.2) [6] Senior notes: ryanho-psych.md (section 7.3) [8] Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (p5, p6, p12) [9] Senior notes: ryanho-psych.md (section 7.1.1) [10] Senior notes: ryanho-psych.md (sections 1.1, 2.2.3, 2.2.4)
Management of Psychotic Symptoms
Management of psychosis follows the same principle as diagnosis: treat the cause, not just the symptom. If the psychosis is secondary to delirium, substance use, or a medical condition, you treat the underlying cause. If it is a primary psychotic disorder, you treat with antipsychotics as the pharmacological mainstay, combined with psychosocial interventions tailored to the phase of illness [2][11].
The biopsychosocial framework is essential — pharmacology alone is insufficient. Think of it as a three-legged stool: biological (antipsychotics, other medications), psychological (CBT, compliance therapy, cognitive remediation), and social (family intervention, rehabilitation, community support). Remove any leg and the stool collapses [2][11].
1. General Principles of Management
- Hospitalisation is necessary for [2][11]:
- First-episode psychosis (FEP) — thorough assessment, establish diagnosis, initiate treatment in a controlled environment
- Severe relapses — risk to self or others, inability to self-care
- Poor insight — patient refusing treatment while clearly deteriorating
- Advantages: thorough assessment, better compliance, relief for family [2]
- Home treatment / community management is possible for less severe episodes and the maintenance phase [2]
| Phase | Goals | Key Interventions |
|---|---|---|
| Acute phase | Control positive symptoms, ensure safety, establish diagnosis | Antipsychotics as mainstay, benzodiazepines for agitation, establish therapeutic relationship, baseline investigations [2][11] |
| Stabilisation phase | Consolidate improvement, minimise relapse risk | Optimise antipsychotic dose, begin psychosocial interventions, address medication side effects |
| Maintenance phase | Prevent relapse, maximise functioning, promote recovery | Continue antipsychotics for at least 1–2 years after first episode, psychosocial interventions (CBT, rehabilitation, family therapy), early intervention programme [2][11] |
2. Pharmacological Treatment
Antipsychotics are also known as neuroleptics and major tranquilisers (as opposed to minor tranquilisers = anxiolytics like benzodiazepines) [2].
- D2 receptor antagonist at the striatum — this is the core mechanism shared by virtually all antipsychotics
- Require only 70–80% blockade of striatal D2 receptors to be therapeutically effective [11]
- ↓Dopaminergic transmission in the mesolimbic pathway → reduces positive symptoms (delusions, hallucinations) [2]
- Problem: D2 blockade is non-selective — it also affects other dopamine pathways:
- Nigrostriatal → extrapyramidal side effects (EPS)
- Tuberoinfundibular → hyperprolactinaemia
- Mesocortical → may worsen negative/cognitive symptoms
- Excessive D2 blockade (> 70–80% of striatal D2 receptors) → motor side effects [11]
- Effective in treating positive psychotic symptoms
- > 80% of patients with first-episode psychosis respond to antipsychotic treatment [11]
- Less effective for negative symptoms, cognitive impairment, and disorganisation
Why Do Antipsychotics Work So Well for Positive Symptoms but Not Negative Symptoms?
Positive symptoms (delusions, hallucinations) arise from mesolimbic hyperdopaminergia — too much dopamine in the reward/salience pathway. D2 blockade here directly counteracts this.
Negative symptoms arise from mesocortical hypodopaminergia — too little dopamine in the prefrontal cortex. D2 blockade here would make things worse, not better. This is why negative symptoms are described as an unmet therapeutic need, not responsive to antipsychotic treatment [1].
Second-generation antipsychotics (SGAs) with 5-HT2A antagonism may partially help because blocking 5-HT2A receptors in the prefrontal cortex disinhibits cortical dopamine release — but even this benefit is modest.
Traditionally divided into generations, but newer evidence suggests this classification has little clinical significance → antipsychotics should be considered individually based on efficacy and side-effect profile [2]:
| Feature | First-Generation Antipsychotics (FGA / "Typical") | Second-Generation Antipsychotics (SGA / "Atypical") |
|---|---|---|
| Mechanism | Predominantly D2 antagonism | D2 antagonism + 5-HT2A antagonism (+ variable receptor profiles) |
| Positive symptoms | Effective | Equally effective (some evidence clozapine and olanzapine may be slightly superior) |
| Negative symptoms | May worsen (secondary negative symptoms from EPS) | Usually SGA > FGA, especially amisulpride, but likely clinically insignificant [2] |
| EPS risk | Higher (especially "high-potency" FGAs) | Lower (especially clozapine, quetiapine, aripiprazole) |
| Metabolic risk | Lower | Higher (especially olanzapine, clozapine) |
| Examples | Haloperidol, chlorpromazine, fluphenazine, flupentixol, zuclopenthixol | Risperidone, olanzapine, quetiapine, aripiprazole, amisulpride, clozapine, paliperidone, lurasidone |
The practical way to think about individual drugs is by their potency concept [2]:
"High-potency" antipsychotics — strong D2 blockade → ↑↑EPS but fewer anti-HAM effects:
- Haloperidol, fluphenazine, risperidone, paliperidone
"Low-potency" antipsychotics — weaker D2 blockade, more action at other receptors → ↓EPS but anti-HAM effects (anti-Histaminergic, anti-Adrenergic, anti-Muscarinic):
- Chlorpromazine, clozapine, olanzapine, quetiapine, aripiprazole [2]
Anti-HAM mnemonic [2]: the three receptor systems responsible for most "low-potency" antipsychotic side effects:
- H₁ (antihistaminergic): sedation, weight gain, drowsiness
- α₁ (anti-adrenergic): postural hypotension, dizziness, reflex tachycardia
- M (antimuscarinic/anticholinergic): dry mouth, constipation, urinary retention, blurred vision, cognitive impairment
Aripiprazole: The Unique Antipsychotic
Aripiprazole (Abilify) is unique in that it is a partial dopamine agonist [2]. Rather than blocking D2 completely, it acts as a "dopamine stabiliser" — in hyperdopaminergic states (mesolimbic), it reduces dopamine signalling; in hypodopaminergic states (mesocortical), it mildly enhances it. This means it has some pro-dopaminergic effects (insomnia, nausea, vomiting) and has minimal D2 + HAM effects [2]. It has the most favourable metabolic profile among all antipsychotics.
Choice of antipsychotic: based on a balance between relative efficacy and side-effect profile [2]:
- Efficacy: clozapine, olanzapine, amisulpride, (risperidone) are more effective among antipsychotics [2]
- Side-effect profile: depends on receptor-binding profile (see table below)
Dosing [2]:
- Minimum dose required to control symptoms (loading dose not recommended)
- Initiation: start at minimal effective dose, consider increasing only after 1–2 weeks of no response
- Slow titration required for quetiapine, iloperidone, and clozapine (risk of hypotension, sedation)
- Always as regular dosing, never as PRN sedatives (prefer other sedatives like benzodiazepines for acute agitation)
Regimen [2]:
- Usually prefer monotherapy — use combination only if absolutely necessary (↑↑side effects)
- No good objective evidence for relative efficacy of combined antipsychotics (apart from clozapine augmentation) over monotherapy [2]
Route of administration [2]:
- Usually oral but can use depot (long-acting injectable, LAI) form for those with problems with non-compliance
- FGA depots: flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate
- SGA depots: aripiprazole, paliperidone palmitate, risperidone
- Efficacy: 30% ↓risk of relapse, presumably due to compliance [2]
- Depot forms should be avoided for elderly and those with ↑risk of overdose/drug interaction due to difficulty in reversal [2]
Maintenance treatment [11]:
- At least 1–2 year maintenance antipsychotic treatment following positive symptom remission is recommended for first-episode psychosis (also depends on individual case)
- High risk of relapse after discontinuation — major risk factor for relapse: non-adherence to medication [11]
- After multiple episodes: most guidelines recommend indefinite treatment (the relapse rate after stopping medication after a first episode is 80–98%) [2]
Monitoring [2]:
- Mental state, physical health, and adverse effects every follow-up
- Metabolic monitoring: BMI, glucose, lipid profile, BP regularly, especially for those on SGA
If poor response [2]:
- Consider: (1) adjusting dose, (2) switching drug, (3) combination therapy
Non-compliance [2]:
- Very common (up to 52%), risk factors include poor insight, negative attitude to medications
- Strategies: depot formulations, compliance therapy (motivational interviewing), simplifying regimen, psychoeducation
| Drug | EPS | Prolactin Elevation | Weight Gain | Key Adverse Effects |
|---|---|---|---|---|
| Amisulpride | + | +++ | + | Insomnia, agitation, nausea, constipation, QT prolongation |
| Sulpiride | + | +++ | +++ | Insomnia, agitation, abnormal LFTs |
| Clozapine | 0 | 0 | +++ | Agranulocytosis (WBC monitoring mandatory), myocarditis (rare), fatigue, drowsiness, dry mouth, sweating, tachycardia, postural hypotension, nausea, constipation/ileus, urinary retention, seizures, diabetes |
| Olanzapine | +/0 | + | +++ | Somnolence, dizziness, oedema, hypotension, dry mouth, constipation, diabetes, QT prolongation |
| Quetiapine | 0 | 0 | ++ | Somnolence, dizziness, postural hypotension, dry mouth, abnormal LFTs, QT prolongation, diabetes |
| Risperidone | ++ | +++ | ++ | Insomnia, agitation, anxiety, headache, impaired concentration, nausea, diabetes, QT prolongation |
| Aripiprazole | + | 0 | 0 | Agitation, insomnia, nausea, vomiting |
| Lurasidone | + | 0 | 0 | Somnolence, insomnia, anxiety, agitation, nausea |
| Haloperidol | +++ | +++ | + | High EPS risk, QT prolongation (especially IV), NMS |
Key pattern to recognise: EPS risk and prolactin elevation tend to go together (both from D2 blockade), while weight gain and metabolic effects correlate with anti-H1 and 5-HT2C antagonism. Aripiprazole and lurasidone are the most metabolically "clean."
EPS arise because antipsychotics block D2 in the nigrostriatal pathway (which normally facilitates voluntary motor control):
| EPS Type | Onset | Mechanism | Features | Management |
|---|---|---|---|---|
| Acute dystonia | Hours to days | Acute D2 blockade in nigrostriatal pathway → imbalance favouring cholinergic activity → sustained muscle contraction | Torticollis, oculogyric crisis, trismus, opisthotonos, laryngospasm (emergency!) | Anticholinergics (benztropine, procyclidine IM/IV) — restores dopamine-acetylcholine balance |
| Parkinsonism | Days to weeks | Chronic D2 blockade mimics dopamine deficiency in nigrostriatal pathway (same mechanism as idiopathic Parkinson's) | Tremor, rigidity (lead-pipe/cogwheel), bradykinesia, shuffling gait, mask-like facies | Reduce dose, switch to lower-potency agent, add anticholinergic |
| Akathisia | Days to weeks | Uncertain — may involve D2 blockade in mesocortical pathway and/or serotonergic mechanisms | Subjective inner restlessness + objective motor restlessness (cannot sit still, pacing, shifting weight) | Reduce dose, switch agent, propranolol (first-line), benzodiazepines, mirtazapine |
| Tardive dyskinesia | Months to years | D2 receptor upregulation from chronic blockade → supersensitivity to dopamine; also possible direct neurotoxicity to basal ganglia | Involuntary choreiform movements, especially orofacial (lip smacking, tongue protrusion, chewing) | Switch to SGA or reduce dose. Stop anticholinergics if any. Consider clozapine, quetiapine. Valbenazine/deutetrabenazine (VMAT2 inhibitors) now approved [2] |
NMS is the most feared complication of antipsychotics — a medical emergency [2]:
- Incidence: 0.01–3%
- Onset: typically 4–11 days after starting or increasing antipsychotic
- Mechanism: severe, sudden D2 blockade in hypothalamus (thermoregulatory centre) and nigrostriatal pathway → loss of dopaminergic thermoregulation + extreme rigidity
- Clinical triad:
- Neuromuscular abnormalities: generalised rigidity (lead-pipe), potentially leading to dysphagia, dyspnoea, with bradyreflexia
- Mental status changes: akinetic mutism, stupor, impaired consciousness
- Autonomic dysfunction: hyperthermia, sweating, tachycardia, unstable blood pressure
- Laboratory: ↑CK (typically > 1000 IU/L), ↑WBC (10–40), ↑LFT, metabolic acidosis
- Mortality: can reach 20% if untreated
- Management:
- Discontinue antipsychotics (will resolve within 1–2 weeks)
- Physical cooling if hyperthermic
- Supportive: IV fluids, treat acute renal failure (from rhabdomyolysis)
- Specific: lorazepam + dantrolene + bromocriptine (or amantadine)
- Consider ECT for treatment of residual psychosis [2]
- D/dx: serotonin syndrome, encephalitis, heat stroke, malignant hyperthermia
NMS vs Serotonin Syndrome
Both present with hyperthermia and altered mental status, but they differ:
- NMS: lead-pipe rigidity, bradyreflexia, ↑CK > 1000, caused by D2 blockade (antipsychotics)
- Serotonin syndrome: clonus, hyperreflexia, myoclonus, diarrhoea, caused by serotonergic excess (SSRIs, MAOIs, tramadol)
- CK is typically higher in NMS than in serotonin syndrome
Treatment-resistant schizophrenia (TRS) affects 10–30% of patients [2][11]:
- Persistent, prominent positive psychotic symptoms
- Despite at least 2 trials of different types of antipsychotic medications
- Of which one is an atypical antipsychotic
- Each trial with adequate dose (maximally tolerated)
- Adequate duration (6–8 weeks) per trial
Treatment of choice = clozapine [2][11]:
- Indication for clozapine initiation = meeting the above TRS definition [11]
- Efficacy: only drug proven to be superior in treatment-resistant patients; response rate ~30% [2]
- Added benefits: ↓suicidal risk, ↓aggression, benefit in those with comorbid substance abuse [2]
Side effects of clozapine [2]:
- Agranulocytosis — may be life-threatening, especially in first 18 weeks
- Anti-HAM effects (sedation, weight gain, hypotension, anticholinergic effects)
- Seizures (dose-related)
- Constipation — can be severe with functional intestinal obstruction (a major cause of clozapine-related death)
- Liver failure, pancreatitis
- Myopericarditis (usually within first month)
- Pulmonary embolism
- Metabolic syndrome (weight gain, diabetes, dyslipidaemia)
Mandatory monitoring [2]:
- Neutrophil count: Q1 week × 18 weeks + Q2 weeks until 1 year + Q4 weeks until end of treatment
Contraindications to clozapine [2]:
- Neutropenia (absolute neutrophil count below threshold)
- Cardiac disease (risk of myocarditis/cardiomyopathy)
- Seizure disorder (clozapine lowers seizure threshold)
If clozapine fails [2]:
- Little consensus on best treatment
- Options: add antipsychotics (clozapine augmentation), ECT augmentation, lamotrigine augmentation
| Agent | Role in Psychosis Management | Mechanism / Rationale |
|---|---|---|
| Benzodiazepines | ↓Behavioural disturbances, ↓aggression, ↓insomnia [2] | GABA-A receptor positive allosteric modulator → anxiolysis, sedation, muscle relaxation. Used as adjunct in acute phase, NOT as long-term monotherapy for psychosis |
| Antidepressants | ?Augmentation in treatment-resistant cases (unproven), especially when significant affective symptoms (e.g., schizoaffective disorder, post-schizophrenia depression) [2] | SSRIs/SNRIs for comorbid depression. Caution: antidepressants alone without mood stabiliser can destabilise bipolar patients |
| Lithium | ?Augmentation in treatment-resistant cases (unproven), especially significant affective symptoms [2] | Mood stabiliser; may be useful in schizoaffective disorder with manic features |
| Mood stabilisers (valproate, carbamazepine, lamotrigine) | Adjunct in schizoaffective disorder, bipolar with psychosis; lamotrigine for clozapine augmentation | Lamotrigine modulates glutamate — rationale for augmenting clozapine given the glutamate hypothesis of schizophrenia |
3. Non-Pharmacological Treatment
Indications: usually as an adjunct to medications aiming to [2][11]:
- ↑Interpersonal and social functioning, especially promotion of independent living in community
- Attenuation of symptomatic severity and associated comorbidities
- Improve treatment compliance
- Rationale: positive symptoms may be amenable to structured reasoning and behavioural modification [2]
- Efficacy: shown to be effective in dealing with residual positive psychotic symptoms (e.g., residual AH) and comorbid depressive and anxiety symptoms [2][11]
- Involves: breaking of thought-behaviour patterns underpinning psychotic symptoms [2]:
- Delusional ideas traced back to origin with alternative explanations explored
- Challenging beliefs about omnipotence and origin of auditory hallucinations
Why does CBT work for psychosis? Even when delusions are "fixed," the distress and behavioural consequences of delusions can be modified. CBT doesn't necessarily eliminate the delusion but helps the patient relate to it differently — reducing distress, reducing dangerous behaviours, and improving functioning.
| Intervention | Purpose | Mechanism / Rationale |
|---|---|---|
| Treatment compliance therapy | ↑Adherence to treatment | Uses motivational interviewing — exploring ambivalence about medication, addressing beliefs about medication, building autonomous motivation [2] |
| Cognitive remediation | ↓Cognitive decline | Mental exercise/training targeting attention, working memory, executive function — strengthens residual cognitive capacity [2][11] |
| Family therapy / intervention | ↓Expressed emotions (EE), ↓caregiver stress and burden, psychoeducation, support [2][11] | High EE (criticism, hostility, emotional over-involvement) → ↑relapse risk. Family therapy targets this directly by teaching communication skills and problem-solving |
| Occupational rehabilitation / vocational support and training / social skills training | Restore functional capacity | Addresses the social and occupational impairment that is the main driver of disability in schizophrenia [11] |
| Community case-management approach | Coordinate multi-disciplinary care in the community | Ensures continuity of care, medication compliance, early detection of relapse [11] |
This is a major focus for mental health service development in the past 20 years [2]:
Rationale [2]:
- Early detection: ↑Duration of untreated psychosis (DUP) predicts poor outcome — it is postulated that active psychosis is neurotoxic and delayed treatment leads to irreversible neurological deterioration [2]
- Phase-specific intervention: allows optimal treatment in the critical period (3–5 years after illness onset)
Local programme in Hong Kong [2]:
- Early Assessment Service for Young People with Psychosis (EASY)
- Eligibility: first-episode psychosis at 15–64 years old
- Duration: covers first 3 years of psychosis, then transferred to general care
- Involves: intensive follow-up with more allied health support and assignment of case managers
- Efficacy: ↓suicide and hospitalisation rates, improved functioning and symptom outcome, ↓default rate [2]
Why Early Intervention Matters
The first 3–5 years after psychosis onset is the "critical period" — this is when the trajectory of the illness is largely determined. Intervening aggressively during this window with intensive support, medication optimisation, and psychosocial interventions can fundamentally alter the long-term course. After this window closes, the illness tends to stabilise (for better or worse), and further intervention has diminishing returns. This is the rationale behind EASY and similar programmes worldwide.
ECT is NOT commonly used in schizophrenia [2] but has specific indications:
- Catatonia — ECT is the gold standard treatment for catatonia unresponsive to benzodiazepines
- Severe comorbid depression (especially with psychotic features or psychomotor retardation — ECT is especially effective for those with psychosis and/or psychomotor retardation [2])
- Treatment-resistant cases — as augmentation to clozapine [2][11]
- Mania or mixed affective states: pregnant patients, life-threatening cases, persistent treatment resistance [2]
- Puerperal psychosis with prominent mood symptoms (rapid treatment to allow reuniting with baby) [2]
Administration [2]:
- Course: 6–12 treatments, 2–3 per week
- Process: short-acting induction agent + muscle relaxant → general anaesthesia → electric pulse delivered via scalp electrodes → generalised tonic-clonic seizure induced, lasting at least 15 seconds
- Unilateral vs bilateral: bilateral more effective but may cause more cognitive impairment
Adverse effects [2]:
- Cognitive impairment: acute confusion, anterograde or retrograde amnesia (generally short-lived, lasting a few days after ECT)
- General complaints: headache, nausea, muscle pain
Mortality: 2–4 per 100,000 (~other minor surgery under GA), usually from cardiopulmonary events [2]
Contraindications: no absolute contraindication, relative contraindications include [2]:
- Heart disease: recent MI, heart failure, ischaemic heart disease
- ↑ICP (raised intracranial pressure)
- Risk of intracranial haemorrhage: hypertension, recent stroke
- Poor anaesthetic risk
| Timeframe | Biological | Psychological | Social |
|---|---|---|---|
| Immediate to short-term | Antipsychotic medication, with benzodiazepines if necessary [2] | Establish therapeutic relationship; support for family (carers) [2] | Admission to hospital; allocation of care coordinator (care programme approach); help with financial, accommodation, social problems [2] |
| Medium to long-term | Review progress in outpatient clinic; consider another antipsychotic then clozapine for non-response; consider depot medication for concordance problems [2] | Relapse prevention work; consider CBT and family therapy [2] | Regular review under care programme approach; consider day hospital; vocational training [2] |
5. Management of Specific Psychotic Disorders (Brief Notes)
- Usually antipsychotics (first-line), CBT (second-line/adjunct) [2]
- More challenging to treat than schizophrenia because patients often have preserved functioning and poor insight into their single delusion — they see no reason to take medication
- Antipsychotics for psychotic symptoms
- Mood stabilisers (lithium, valproate) or antidepressants depending on whether manic or depressive type
- Combination approach addressing both mood and psychotic components
- Psychotic depression: antidepressant + antipsychotic (combination more effective than either alone); ECT if severe/treatment-resistant
- Mania with psychotic features: mood stabiliser (lithium, valproate) + antipsychotic; consider hospitalisation [8]
- Short-term antipsychotic treatment (may only need weeks to months)
- Supportive psychotherapy
- Close follow-up (proportion will develop schizophrenia)
- Treat the underlying cause — this is paramount
- Antipsychotics only as adjunct for behavioural management (e.g., haloperidol first-line for delirium; avoid benzodiazepines except in alcohol/benzodiazepine withdrawal) [2]
- For delirium: non-pharmacological measures are the mainstay (reorientation, familiar environment, appropriate lighting) [2]
| Treatment | Indications | Contraindications / Cautions |
|---|---|---|
| Antipsychotics (general) | Psychosis (any cause), behavioural disturbance in dementia/delirium, mood stabilisation in bipolar, augmentation in mood/anxiety disorders [2] | Caution in QT prolongation, Lewy body dementia (extreme sensitivity → avoid typical antipsychotics), Parkinson's disease, elderly with dementia (↑cerebrovascular risk) |
| Clozapine | Treatment-resistant schizophrenia (failed ≥2 adequate trials) [2][11] | Neutropenia, cardiac disease, seizure disorder [2]. Also: paralytic ileus, uncontrolled epilepsy |
| Depot antipsychotics | Non-compliance, frequent relapses due to medication non-adherence [2] | Avoid in elderly and those at ↑risk of overdose/drug interaction (difficulty in reversal) [2] |
| Benzodiazepines | Acute agitation, catatonia (lorazepam first-line), alcohol withdrawal, anxiety, insomnia [2] | Respiratory depression, severe hepatic impairment, myasthenia gravis, sleep apnoea. Caution in elderly (falls, paradoxical disinhibition) |
| ECT | Catatonia, severe depression (especially with psychosis/psychomotor retardation), treatment-resistant schizophrenia (augmentation), mania (pregnant/life-threatening), puerperal psychosis [2] | Relative: recent MI, ↑ICP, risk of ICH, poor anaesthetic risk. No absolute contraindication [2] |
| CBT for psychosis | Residual positive symptoms (e.g., residual AH), comorbid depressive/anxiety symptoms [2][11] | Acute psychosis with no insight (cannot engage meaningfully); severe cognitive impairment |
| Family therapy | Patients in high-EE environments; caregiver stress and burden [2][11] | Family unwilling/unable to participate |
High Yield Summary — Management of Psychotic Symptoms
-
Always treat the cause: secondary psychosis → treat underlying condition; primary psychosis → antipsychotics + psychosocial interventions.
-
Antipsychotics are the mainstay: D2 receptor antagonists; > 80% FEP respond; effective for positive symptoms but NOT negative symptoms.
-
Choice of antipsychotic: based on efficacy vs side-effect profile. High potency (haloperidol, risperidone) → more EPS, less sedation. Low potency (olanzapine, quetiapine, clozapine) → less EPS, more anti-HAM effects.
-
Maintenance: at least 1–2 years after first episode; longer/indefinite after multiple episodes. Non-adherence is the biggest risk factor for relapse → consider depot formulations.
-
Treatment-resistant schizophrenia: failed ≥2 adequate trials (including ≥1 atypical) → clozapine (only drug proven superior). Monitor neutrophils: weekly × 18 weeks, then fortnightly × 1 year, then monthly.
-
Clozapine side effects: agranulocytosis, myocarditis, seizures, severe constipation/ileus, metabolic syndrome. C/I: neutropenia, cardiac disease, seizure disorder.
-
NMS: medical emergency — rigidity, hyperthermia, altered consciousness, ↑CK. Stop antipsychotic, dantrolene + bromocriptine + lorazepam.
-
Non-pharmacological: CBT for residual symptoms, compliance therapy, cognitive remediation, family therapy (↓EE), vocational rehabilitation.
-
Early intervention (EASY in HK): first 3 years of FEP, intensive support → reduces DUP, ↓suicide, ↓hospitalisation.
-
ECT: catatonia, severe psychotic depression, treatment-resistant schizophrenia (augmentation). No absolute contraindication.
Active Recall - Management of Psychotic Symptoms
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p10) [2] Senior notes: ryanho-psych.md (sections 6.2C, 3.1.2, ECT section, delirium management) [8] Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (p18) [11] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p23, p24)
Complications of Psychotic Disorders
Complications of psychosis are not just "things that go wrong" — they are the inevitable downstream consequences of a chronic brain disorder that impairs thinking, motivation, social engagement, and physical self-care, compounded by the side effects of the very medications used to treat it. Understanding complications from first principles means tracing each one back to either the disease process itself, the treatment, or the interaction between illness and society.
These complications fall into five broad domains:
- Psychiatric complications (suicide, comorbidity, treatment resistance)
- Physical health complications (metabolic syndrome, cardiovascular disease, medication side effects)
- Cognitive and functional complications (progressive decline, disability)
- Social complications (stigma, homelessness, legal issues, caregiver burden)
- Treatment-related complications (medication side effects, NMS, tardive dyskinesia)
1. Psychiatric Complications
This is the most devastating and preventable complication of psychotic disorders.
- Suicide is the single largest cause of premature death in schizophrenia [1][2]
- 5.6% lifetime suicide rate (based on first-episode cohorts); 4.9% from all studies [1]
- Risk is highest in the early stage of psychotic disorders [1]
- Rate is highest in the first year after presentation of FEP (first-episode psychosis) [1]
- Suicide risk of psychotic patients is 12 times more than expected from the general population [1]
- Depressed mood, one of the strongest predictors of suicide, is frequently observed in the early stage of illness [1]
Why is the risk highest early in the illness?
- The patient may retain enough insight to recognise the devastating implications of their diagnosis — loss of career prospects, relationships, identity. This "insight-depression paradox" is a known phenomenon: recovery of insight into illness and its problems in the post-psychotic phase can itself precipitate depression and suicidality [2].
- Depressed mood is extremely common early in schizophrenia — it may be an integral part of the illness, a reaction to emerging insight, or a medication side effect [2].
- Patients who were previously high-functioning (e.g., young men with good education) are particularly at risk because the gap between their premorbid expectations and their post-illness reality is greatest [2].
Risk factors for suicide in psychosis [2]:
- Depressed mood (strongest predictor)
- First year of illness / first episode
- Young, male, previously high-functioning
- Previous suicide attempts
- Substance abuse (comorbid)
- Command hallucinations (voices telling patient to harm themselves)
- Persecutory delusions (sense of being trapped)
- Poor adherence to treatment
- Social isolation
- Recent discharge from hospital (transition period with reduced support)
Suicide After Hospital Discharge
The period immediately following discharge from a psychiatric ward is one of the highest-risk periods for suicide. The patient transitions from a structured, supervised environment to the community, often with incomplete recovery and inadequate follow-up. This is why the EASY programme and other early intervention services emphasise intensive follow-up in the community — to bridge this dangerous gap [2].
- 25% of schizophrenia patients suffer from post-schizophrenia depression [2]
- Explanations include [2]:
- Depression may be an integral part of the schizophrenic illness (shared neurobiology — both involve monoamine dysfunction)
- May result from recovery of insight into illness and its consequences in the post-psychotic phase
- May be a side effect of medications (especially FGAs causing secondary negative symptoms that mimic depression)
- Significance: depression ↑suicide risk, ↑functional impairment, ↓quality of life, ↓medication compliance
- 30% of schizophrenia patients abuse alcohol [12]
- Alcohol temporarily decreases feelings of isolation and reduces symptoms of anxiety, depression, and insomnia in schizophrenic patients [12]
- However, alcohol increases psychotic symptoms and mood swings [12]
- Consequences [12]:
- Disruptive behaviour, suicide
- Treatment non-compliance
- Drug abuse (gateway effect)
- Poor clinical outcome
- Drug accumulation due to hepatic damage (liver impairment from alcohol alters metabolism of antipsychotics)
- Cannabis, methamphetamine, and other stimulants are also commonly abused — all worsen psychotic symptoms via dopaminergic mechanisms
- Comorbid substance abuse is a poor prognostic factor [1][2]
- 30% of schizophrenia patients are treatment-resistant [2]
- Even with clozapine (the gold standard for TRS), only ~30% respond [2]
- This means approximately 10% of all schizophrenia patients fail all available pharmacological treatments
- Treatment resistance is associated with:
- More severe illness at onset
- Prominent negative and cognitive symptoms
- Prolonged DUP
- Poor premorbid adjustment
- Substance abuse
- High risk of relapse after medication discontinuation [11]
- Major risk factor for relapse: non-adherence to medication [11]
- Non-compliance is very common (up to 52%), with risk factors including poor insight and negative attitudes to medication [2]
- Each relapse is thought to cause further neurological damage — the neuroprogression theory [13]:
Neuroprogression in Psychosis
Neuroprogression theory proposes that each psychotic episode causes incremental, potentially irreversible brain damage [13]. This is supported by the observation that active psychosis is neurotoxic and delayed treatment leads to irreversible neurological deterioration [2]. This is the fundamental rationale for:
- Minimising duration of untreated psychosis (DUP)
- Early intervention (EASY programme)
- Maintenance antipsychotic treatment to prevent relapse
- Aggressive treatment of breakthrough symptoms
2. Physical Health Complications
- Lifespan reduced by 10–15 years on average [2]
- 2.6× all-cause mortality, with the majority being non-suicidal causes [2]
The reasons are multifactorial [2]:
| Factor | Mechanism | Examples |
|---|---|---|
| Lifestyle | Sedentary behaviour, poor nutrition | Negative symptoms (avolition, apathy) → patients lack motivation to exercise or eat healthily |
| Substance use | Smoking, substance/alcohol abuse | ~60–80% of schizophrenia patients smoke (vs ~20% general population). Nicotine may partially self-medicate cognitive symptoms (nicotinic receptor stimulation ↑attention). Smoking → lung cancer, COPD, CVD |
| Medication side effects | Metabolic syndrome related to 2nd-generation antipsychotics | Weight gain, insulin resistance, dyslipidaemia → diabetes, CVD, stroke |
| Inherent disease process | ?Accelerated ageing, ↑medical morbidity | Emerging evidence of accelerated biological ageing in schizophrenia (telomere shortening, oxidative stress) |
| Healthcare access | Diagnostic overshadowing, poor help-seeking | Physical complaints attributed to psychiatric illness ("it's just his schizophrenia"); patients less likely to seek medical care; physicians less likely to investigate |
This is the most important iatrogenic physical complication — directly caused by the medications we prescribe:
- Higher risk of cardiovascular and metabolic diseases (obesity, diabetes, hypercholesterolaemia) than the general population [13]
- Risk factors for medical comorbidity [13]:
- Alcohol and substance use
- Unhealthy diet
- Physical inactivity
- Social isolation, unemployment, and low education and socioeconomic status
- Stress
- Poor sleep and mental health
- Childhood abuse
- Side effects of pharmacotherapy, e.g., sodium valproate, atypical antipsychotics [13]
The worst offenders for metabolic side effects are clozapine and olanzapine (+++ weight gain, diabetes, dyslipidaemia), followed by quetiapine (++) and risperidone (++) [2]. Aripiprazole and lurasidone are the most metabolically neutral [2].
Why do SGAs cause metabolic syndrome? They antagonise 5-HT2C receptors and H1 receptors in the hypothalamus, disrupting appetite regulation and energy homeostasis → ↑food intake, ↓satiety, ↑fat deposition (especially visceral). They also have direct effects on pancreatic beta cells (↓insulin secretion) and on hepatic lipid metabolism.
Metabolic monitoring is therefore mandatory [2]:
- BMI, glucose, lipid profile, blood pressure regularly, especially for those on SGA
- Typically: baseline → 3 months → 6 months → annually
- Leading cause of excess non-suicidal mortality in schizophrenia
- Driven by metabolic syndrome (above) + smoking + sedentary lifestyle
- QTc prolongation from antipsychotics (especially amisulpride, haloperidol IV, ziprasidone) → risk of torsades de pointes → sudden cardiac death [2]
- Myocarditis/cardiomyopathy — rare but serious complication of clozapine (usually within first month) [2]
3. Cognitive and Functional Complications
Cognitive impairment is a core feature of schizophrenia and represents one of the most disabling aspects of the illness [1]:
- A core feature in schizophrenia [1]
- Key determinant of functional outcome [1]
- Unmet therapeutic need, not responsive to antipsychotic treatment [1]
- Generalised cognitive impairment encompassing multiple cognitive domains [1]:
- Sustained attention
- Executive functions (planning, set-shifting, inhibition control)
- Working memory
- Verbal and visual memory (immediate registration and recall)
- Processing speed
- In general, 1–2 standard deviations below normal healthy controls [1]
- Healthy first-degree relatives of patients also demonstrate deficits (albeit less severe) in cognition [1] — suggesting cognitive impairment is related to genetic vulnerability, not just the illness itself
- Impairment in social cognition observed, including deficits in theory of mind (ToM), emotion recognition, etc. [1]
Why is this so devastating functionally? Cognitive impairment affects every domain of daily life — the ability to hold a job (sustained attention, executive function), manage finances (working memory, planning), maintain relationships (social cognition, ToM), and live independently. Unlike positive symptoms, which respond well to antipsychotics, cognitive impairment is not responsive to current treatments and is the primary driver of long-term disability.
- Schizophrenia is the No. 12 leading disability worldwide and accounts for substantial direct and indirect costs [2]
- Functional impairment encompasses:
- Occupational: inability to maintain employment (most devastating in young-onset illness)
- Social: social withdrawal, inability to maintain relationships
- Self-care: poor hygiene, nutrition, housing management (driven by negative symptoms)
- Educational: onset in adolescence/early adulthood disrupts education at the most critical period
- > 50% have poor outcome [2]
- Functional outcome is more closely correlated with negative symptoms and cognitive impairment than with positive symptoms [1][2]
The staging of illness concept from bipolar disorder research also applies to schizophrenia [13]:
- Stage 1: high-risk group or subsyndromal symptoms
- Stage 2: few episodes, optimal functioning
- Stage 3: recurrent episodes and decline in functioning and cognition
- Neuroprogression theory: worse prognosis with frequent relapses [13]
- Increased risk of future development of dementia [13]
This is consistent with the observation that each psychotic episode is associated with progressive grey matter loss and ventricular enlargement.
4. Social Complications
- Despite the renaming to 思覺失調 in Hong Kong (2001) to reduce stigma, psychotic disorders remain heavily stigmatised
- Patients face discrimination in employment, housing, relationships, and healthcare
- Self-stigma (internalised shame) further worsens depression, social withdrawal, and treatment non-adherence
- Stigma is one of the main barriers to help-seeking, especially in Asian cultures
- Psychotic disorders are over-represented among homeless populations
- The combination of functional impairment, unemployment, social isolation, and poor family support creates a downward spiral
- In Hong Kong, social welfare support and halfway houses are critical safety nets
- Patients with psychotic disorders have a modestly increased risk of violence compared to the general population — but the absolute risk remains low
- Risk is primarily driven by: comorbid substance abuse, acute positive symptoms (especially persecutory delusions with perceived threat, command hallucinations), and treatment non-adherence
- The much greater issue is that patients with psychosis are far more likely to be victims of violence than perpetrators
- Caring for a family member with chronic psychosis is enormously stressful
- High expressed emotions (EE) of caregivers — critical, hostile, emotionally over-involved attitudes — are both a consequence of caregiver stress AND a cause of patient relapse (↑risk of relapse if exposed to high EE > 35 hours/week) [2]
- Family intervention (psychoeducation, expressed emotion reduction, support) is a core component of management precisely because it addresses this vicious cycle [11]
These have been covered in detail in the management section but are summarised here for completeness as they represent a major source of morbidity:
| Complication | Mechanism | Offending Agents | Consequences |
|---|---|---|---|
| Extrapyramidal side effects | D2 blockade in nigrostriatal pathway | High-potency FGAs (haloperidol), risperidone | Acute dystonia, parkinsonism, akathisia, tardive dyskinesia |
| Tardive dyskinesia | Chronic D2 blockade → receptor upregulation → supersensitivity | All antipsychotics (especially long-term FGAs) | Irreversible involuntary orofacial movements; profoundly stigmatising |
| Neuroleptic malignant syndrome | Sudden severe D2 blockade in hypothalamus + nigrostriatal | Any antipsychotic (especially high-potency, rapid dose escalation) | Mortality up to 20% if untreated [2] |
| Metabolic syndrome | H1, 5-HT2C antagonism → appetite dysregulation; direct metabolic effects | Clozapine, olanzapine > quetiapine, risperidone | Obesity, diabetes, dyslipidaemia → CVD |
| Hyperprolactinaemia | D2 blockade in tuberoinfundibular pathway → loss of tonic prolactin inhibition | Amisulpride, risperidone, paliperidone, haloperidol | Galactorrhoea, amenorrhoea, sexual dysfunction, osteoporosis (long-term) |
| QTc prolongation | Blockade of cardiac hERG potassium channels | Amisulpride, haloperidol (IV), ziprasidone | Torsades de pointes → sudden cardiac death |
| Sedation | H1 antagonism | Chlorpromazine, quetiapine, olanzapine, clozapine | Falls (especially elderly), cognitive impairment, reduced functioning |
| Agranulocytosis | Immune-mediated destruction of neutrophils | Clozapine (risk ~1%, especially first 18 weeks) | Life-threatening infection if not detected; mandatory monitoring [2] |
| Constipation / functional ileus | Antimuscarinic effects on GI smooth muscle | Clozapine | Can be fatal if not recognised; clozapine-related bowel obstruction is a significant cause of death |
| Myocarditis / cardiomyopathy | Direct toxic effect on myocardium (mechanism not fully understood) | Clozapine (usually first month) | Chest pain, dyspnoea, fever, tachycardia; can be fatal |
The Underappreciated Danger of Clozapine-Related Constipation
Clozapine causes severe constipation in up to 60% of patients due to potent antimuscarinic effects on gut motility. This can progress to functional intestinal obstruction (paralytic ileus), bowel perforation, and death. Clozapine-related GI complications may actually cause more deaths than agranulocytosis in some series. Always assess bowel function in patients on clozapine, prescribe laxatives prophylactically, and educate patients and carers.
For completeness, since psychosis can arise from mood disorders [13]:
Bipolar disorder complications:
- Poor prognosis: only < 20% achieve a 5-year period of clinical stability [2]
- Poor prognostic factors: early onset, greater severity, mixed episodes, repeated episodes, previous hospitalisations, residual symptoms, cognitive impairment, poor insight, side effects of medications, comorbid substance or personality disorder [13]
- Mortality significantly ↑; ↓life expectancy by ~13 years (M) and 9 years (F) [2]
- Suicide: ~8% (M) and 5% (F) hospitalised patients die by suicide over 40 years [2]
- Medical comorbidity: ↑CVS disease/metabolic syndrome (medication side effects, poor lifestyle), consequences of comorbid substance abuse and smoking [2]
Underdiagnosis complications [13]:
- The distress caused by untreated mood symptoms results in increased suicidality, comorbid anxiety and substance use disorders [13]
- Poor QOL, greater functional impairment, and increased healthcare cost [13]
- Antidepressant monotherapy is less effective and results in manic switch and cycle acceleration [13]
Course: highly heterogeneous, usually chronic and relapsing-remitting [2]
Prognosis: 30% treatment-resistant, 20% remission, 10% suicide, > 50% have poor outcome [2]
Poor prognostic factors [1][2]:
| Patient Factors | Disease Factors | Other Factors |
|---|---|---|
| Poor premorbid adjustment [1] | Insidious onset of psychosis [1] | High expressed emotions (EE) of caregivers [1] |
| Early onset / young age of onset [1] | Prolonged duration of untreated psychosis (DUP) [1] | Comorbid substance abuse [1] |
| Male gender [1] | Prominent negative symptoms [1] | Poor initial treatment response to antipsychotic medication [1] |
| Single [2] | Severe cognitive impairment [1] | Poor treatment adherence [2] |
| Family history [2] | Hebephrenic subtype [1] | |
| Prominent affective symptoms [2] | ||
| Poor insight [2] |
High Yield Summary — Complications of Psychotic Disorders
-
Suicide: single largest cause of premature death in schizophrenia; 5.6% lifetime risk; highest in first year of FEP; depressed mood is strongest predictor; 12× general population risk.
-
Premature mortality: 10–15 years reduced lifespan; 2.6× all-cause mortality; majority non-suicidal — driven by CVD, metabolic syndrome (antipsychotic side effects), smoking, sedentary lifestyle.
-
Metabolic syndrome: worst with clozapine and olanzapine; mandatory metabolic monitoring on all SGAs (BMI, glucose, lipids, BP).
-
Cognitive impairment: core feature; 1–2 SD below normal; encompasses attention, executive function, working memory, processing speed, social cognition; key determinant of functional outcome; unresponsive to antipsychotics.
-
Treatment resistance: 30% of patients; clozapine is the only proven superior treatment (response ~30%).
-
Neuroprogression: frequent relapses worsen prognosis; increased risk of dementia; rationale for early intervention and maintenance treatment.
-
Substance abuse: 30% of schizophrenia patients abuse alcohol; worsens psychotic symptoms, treatment adherence, and outcome.
-
Treatment complications: EPS (acute dystonia, parkinsonism, akathisia, tardive dyskinesia), NMS (medical emergency, 20% mortality if untreated), agranulocytosis (clozapine), QTc prolongation, constipation/ileus (clozapine), myocarditis (clozapine).
-
Social complications: stigma, unemployment, homelessness, caregiver burden, high EE environment → relapse.
-
Poor prognostic factors: poor premorbid adjustment, male, young onset, insidious onset, prolonged DUP, prominent negative/cognitive symptoms, hebephrenic subtype, substance abuse, high EE, poor treatment response.
Active Recall - Complications of Psychotic Disorders
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p10, p11, p12, p23, p25, p26) [2] Senior notes: ryanho-psych.md (sections 6.2, 6.2C) [11] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (p23, p24) [12] Lecture slides: GC 161. Alcohol and the Brain From Psychiatric to Neuropsychiatric Perspectives.pdf (p44) [13] Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (p14, p27, p34, p49)
High Yield Summary
-
Psychosis is a syndrome, not a diagnosis — always identify the underlying cause (schizophrenia, mood disorder, organic, substance).
-
Four cardinal features: delusions, hallucinations, disorganisation, lack of insight.
-
Epidemiology: ~1% lifetime risk for schizophrenia; 2.5% all psychotic disorders in HK; M:F = 1.4:1; onset late adolescence/early adulthood; 10–15 year reduced lifespan.
-
Dopamine hypothesis: mesolimbic hyperdopaminergia → positive symptoms; mesocortical hypodopaminergia → negative/cognitive symptoms. Also involves glutamate (NMDA hypofunction), GABA, serotonin.
-
Neurodevelopmental hypothesis: schizophrenia is a disorder of brain development (not degeneration) — supported by absence of gliosis, premorbid deficits, prenatal risk factors.
-
Stress-vulnerability model: genetic vulnerability + environmental stressors → psychosis.
-
Classification hierarchy: Organic → Mood disorder with psychosis → Schizoaffective → Schizophrenia → Schizophreniform → ATPD → Delusional disorder → Schizotypal.
-
Negative symptoms (5 A's): affect flattening, alogia, anhedonia, avolition, asociality. Primary (core, treatment-resistant) vs secondary (treatable cause).
-
Schneider's FRS (SPECTRA): somatic passivity, passivity phenomena, echo of thought, commentary, thought insertion/withdrawal/broadcasting, delusional perception/reference, 3rd person AH.
-
Always exclude organic psychosis: visual hallucinations, clouded consciousness, disorientation, abnormal vitals, new neuro signs, age > 40 → think medical cause first.
High Yield Summary — Differential Diagnosis of Psychotic Symptoms
-
Always exclude organic causes first — especially delirium, substance-induced psychosis, and medical conditions (TFT, glucose, B12, syphilis, neuroimaging).
-
Visual hallucinations + clouded consciousness + disorientation = think organic, not primary psychosis.
-
Mood-congruent psychosis that occurs only during mood episodes = mood disorder with psychotic features. Psychosis persisting ≥2 weeks outside mood episodes = schizoaffective.
-
Duration hierarchy: ATPD (< 1 month) → schizophreniform (1–6 months) → schizophrenia (≥ 6 months).
-
Delusional disorder: isolated, single-theme, non-bizarre delusion; minimal other symptoms; preserved functioning.
-
Mania with psychosis is commonly misdiagnosed as schizophrenia — look for episodic course, mood-congruent delusions, flight of ideas (logical links preserved), pressured speech, ↓need for sleep.
-
Anti-NMDA receptor encephalitis is the great mimicker in young women with new-onset psychosis — always consider if atypical features develop (seizures, movement disorder, autonomic instability).
-
FRS are not pathognomonic for schizophrenia — they occur in mania (10–20%, fleeting) and other psychoses. But they remain widely applied in classification.
High Yield Summary — Diagnostic Criteria and Investigations
-
DSM-5 schizophrenia: ≥2 of 5 symptoms (at least 1 must be delusions, hallucinations, or disorganised speech), ≥1 month active + ≥6 months total, functional impairment, exclude schizoaffective/mood disorder, exclude organic/substance.
-
ICD-10 schizophrenia: 1 of FRS (a–d) OR 2 of lesser symptoms (e–i), ≥1 month. FRS are given more diagnostic weight in ICD-10 than in DSM-5.
-
Schizoaffective key criterion: psychosis must persist ≥2 weeks OUTSIDE mood episodes (otherwise it's mood disorder with psychosis).
-
Duration hierarchy: Brief psychotic disorder (< 1 month) → Schizophreniform (1–6 months) → Schizophrenia (≥ 6 months).
-
Mania: ≥1 week of elevated/irritable mood + ≥3 symptoms + marked impairment. Hypomania: ≥4 days + ≥3 symptoms + NO marked impairment and NO psychotic features.
-
Investigations are for exclusion (organic causes) and baseline (before medication). No test confirms a primary psychotic disorder.
-
Mandatory first-line: CBC, RFT (+ Ca²⁺), LFT, TFT, fasting glucose/lipids, urine drug screen, ECG.
-
Extended (if red flags): CT/MRI brain, EEG, B12/folate, VDRL, HIV, ESR/CRP, LP, autoimmune antibodies.
-
Hierarchy of diagnosis: organic > psychotic > mood > anxiety > personality — always exclude higher-order causes first.
High Yield Summary — Management of Psychotic Symptoms
-
Always treat the cause: secondary psychosis → treat underlying condition; primary psychosis → antipsychotics + psychosocial interventions.
-
Antipsychotics are the mainstay: D2 receptor antagonists; > 80% FEP respond; effective for positive symptoms but NOT negative symptoms.
-
Choice of antipsychotic: based on efficacy vs side-effect profile. High potency (haloperidol, risperidone) → more EPS, less sedation. Low potency (olanzapine, quetiapine, clozapine) → less EPS, more anti-HAM effects.
-
Maintenance: at least 1–2 years after first episode; longer/indefinite after multiple episodes. Non-adherence is the biggest risk factor for relapse → consider depot formulations.
-
Treatment-resistant schizophrenia: failed ≥2 adequate trials (including ≥1 atypical) → clozapine (only drug proven superior). Monitor neutrophils: weekly × 18 weeks, then fortnightly × 1 year, then monthly.
-
Clozapine side effects: agranulocytosis, myocarditis, seizures, severe constipation/ileus, metabolic syndrome. C/I: neutropenia, cardiac disease, seizure disorder.
-
NMS: medical emergency — rigidity, hyperthermia, altered consciousness, ↑CK. Stop antipsychotic, dantrolene + bromocriptine + lorazepam.
-
Non-pharmacological: CBT for residual symptoms, compliance therapy, cognitive remediation, family therapy (↓EE), vocational rehabilitation.
-
Early intervention (EASY in HK): first 3 years of FEP, intensive support → reduces DUP, ↓suicide, ↓hospitalisation.
-
ECT: catatonia, severe psychotic depression, treatment-resistant schizophrenia (augmentation). No absolute contraindication.
High Yield Summary — Complications of Psychotic Disorders
-
Suicide: single largest cause of premature death in schizophrenia; 5.6% lifetime risk; highest in first year of FEP; depressed mood is strongest predictor; 12× general population risk.
-
Premature mortality: 10–15 years reduced lifespan; 2.6× all-cause mortality; majority non-suicidal — driven by CVD, metabolic syndrome (antipsychotic side effects), smoking, sedentary lifestyle.
-
Metabolic syndrome: worst with clozapine and olanzapine; mandatory metabolic monitoring on all SGAs (BMI, glucose, lipids, BP).
-
Cognitive impairment: core feature; 1–2 SD below normal; encompasses attention, executive function, working memory, processing speed, social cognition; key determinant of functional outcome; unresponsive to antipsychotics.
-
Treatment resistance: 30% of patients; clozapine is the only proven superior treatment (response ~30%).
-
Neuroprogression: frequent relapses worsen prognosis; increased risk of dementia; rationale for early intervention and maintenance treatment.
-
Substance abuse: 30% of schizophrenia patients abuse alcohol; worsens psychotic symptoms, treatment adherence, and outcome.
-
Treatment complications: EPS (acute dystonia, parkinsonism, akathisia, tardive dyskinesia), NMS (medical emergency, 20% mortality if untreated), agranulocytosis (clozapine), QTc prolongation, constipation/ileus (clozapine), myocarditis (clozapine).
-
Social complications: stigma, unemployment, homelessness, caregiver burden, high EE environment → relapse.
-
Poor prognostic factors: poor premorbid adjustment, male, young onset, insidious onset, prolonged DUP, prominent negative/cognitive symptoms, hebephrenic subtype, substance abuse, high EE, poor treatment response.
Personality And Personality Disorders
Personality refers to enduring patterns of perceiving, relating to, and thinking about oneself and the environment, while personality disorders are inflexible, maladaptive patterns of inner experience and behavior that deviate markedly from cultural expectations, cause significant distress or functional impairment, and are typically evident by early adulthood.
Schizophrenia And Related Disorders
Schizophrenia and related disorders are a group of chronic psychiatric conditions characterized by disturbances in thought, perception, affect, and behavior, including symptoms such as delusions, hallucinations, disorganized thinking, and negative symptoms.